- Click on the title of each paper to access MedLine abstract at NLM site
Ulcerative Colitis - Medical treatment and research

                                                          <return>

Passive smoking and inflammatory bowel disease: a meta-analysis. Jones DT, Osterman MT, Bewtra M, Lewis JD. Am J Gastroenterol. 2008 Sep;103(9):2382-93.

Imbalance in intestinal microflora constitution could be involved in the pathogenesis of inflammatory bowel disease. Takaishi H, Matsuki T, Nakazawa A, Takada T, Kado S, Asahara T, Kamada N, Sakuraba A, Yajima T, Higuchi H, Inoue N, Ogata H, Iwao Y, Nomoto K, Tanaka R, Hibi T. Int J Med Microbiol. 2008 Jul;298(5-6):463-72.

Brackmann S, Andersen SN, Aamodt G, Langmark F, Clausen OP, Aadland E, Fausa O, Rydning A, Vatn MH.

Von Stein P, Lofberg R, Kuznetsov NV, Gielen AW, Persson JO, Sundberg R, Hellstrom K, Eriksson A, Befrits R, Ost A, Von Stein OD. Multigene Analysis Can Discriminate Between Ulcerative Colitis, Crohn's Disease, and Irritable Bowel Syndrome. Gastroenterology. 2008 Mar 2.

Hawthorne AB, Rubin G, Ghosh S. Review article: medication non-adherence in ulcerative colitis--strategies to improve adherence with mesalazine and other maintenance therapies. Aliment Pharmacol Ther. 2008 Jun;27(12):1157-66.

Harada A, Ohkusa T, Kushima K, Sakamoto M, Benno Y, Beppu K, Shibuya T, Sakamoto N, Watanabe S. Identification of bacteria from blood in febrile patients with ulcerative colitis by terminal restriction fragment length polymorphism profile analysis of 16S rRNA gene. Scand J Gastroenterol. 2008;43(4):423-30.

Lichtenstein GR, Kamm MA, Sandborn WJ, Lyne A, Joseph RE. MMX mesalazine for the induction of remission of mild-to-moderately active ulcerative colitis: efficacy and tolerability in specific patient subpopulations. Aliment Pharmacol Ther. 2008 Jun 1;27(11):1094-102.

Hart AR, Luben R, Olsen A, Tjonneland A, Linseisen J, Nagel G, Berglund G, Lindgren S, Grip O, Key T, Appleby P, Bergmann MM, Boeing H, Hallmans G, Danielsson A, Palmqvist R, Sjodin H, Hagglund G, Overvad K, Palli D, Masala G, Riboli E, Kennedy H, Welch A, Khaw KT, Day N, Bingham S. Diet in the aetiology of ulcerative colitis: a European prospective cohort study. Digestion. 2008;77(1):57-64.

Lutgens MW, Vleggaar FP, Schipper ME, Stokkers PC, van der Woude J, Hommes DW, de Jong DJ, Dijkstra G, van Bodegraven AA, Oldenburg B, Samsom M. High Frequency of Early Colorectal Cancer in Inflammatory Bowel Disease. Gut. 2008 Mar 12.

Lewis JD, Lichtenstein GR, Deren JJ, Sands BE, Hanauer SB, Katz JA, Lashner B, Present DH, Chuai S, Ellenberg JH, Nessel L, Wu GD; Rosiglitazone for Ulcerative Colitis Study Group. Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial. Gastroenterology. 2008 Mar;134(3):688-95.

Hanai H, Iida T, Takeuchi K, Watanabe F, Maruyama Y, Kageoka M, Ikeya K, Yamada M, Kikuyama M, Iwaoka Y, Hirayama K, Nagata S, Sato Y, Hosoda Y. Intensive granulocyte and monocyte adsorption versus intravenous prednisolone in patients with severe ulcerative colitis: An unblinded randomised multi-centre controlled study. Dig Liver Dis. 2008 Jun;40(6):433-40.

James SL, Irving PM, Gearry RB, Gibson PR. Management of distal ulcerative colitis: frequently asked questions analysis. Intern Med J. 2008 Feb;38(2):114-9. Review.

Flasar MH, Quezada S, Bijpuria P, Cross RK. Racial Differences in Disease Extent and Severity in Patients with Ulcerative Colitis: A Retrospective Cohort Study. Dig Dis Sci. 2008 Feb 14.

Mitsuyama K, Sata M. Gut microflora: a new target for therapeutic approaches in inflammatory bowel disease. Expert Opin Ther Targets. 2008 Mar;12(3):301-12. Review.

Mahid SS, Mulhall AM, Gholson RD, Eichenberger MR, Galandiuk S. Inflammatory bowel disease and African Americans: A systematic review. Inflamm Bowel Dis. 2008 Feb 11.

Yamamoto T, Maruyama Y, Umegae S, Matsumoto K, Saniabadi AR. Mucosal inflammation in the terminal ileum of ulcerative colitis patients: endoscopic findings and cytokine profiles. Dig Liver Dis. 2008 Apr;40(4):253-9.

Baumgart DC. What's new in inflammatory bowel disease in 2008? World J Gastroenterol. 2008 Jan 21;14(3):329-30.

Kane SV, Reddy D. Hormonal replacement therapy after menopause is protective of disease activity in women with inflammatory bowel disease. Am J Gastroenterol. 2008 May;103(5):1193-6.

Xiang JY, Ouyang Q, Li GD, Xiao NP. Clinical value of fecal calprotectin in determining disease activity of ulcerative colitis. World J Gastroenterol. 2008 Jan 7;14(1):53-7.

Melmed GY, Fleshner PR, Bardakcioglu O, Ippoliti A, Vasiliauskas EA, Papadakis KA, Dubinsky M, Landers C, Rotter JI, Targan SR. Family history and serology predict Crohn's disease after ileal pouch-anal anastomosis for ulcerative colitis. Dis Colon Rectum. 2008 Jan;51(1):100-8.

Swidsinski A, Loening-Baucke V, Vaneechoutte M, Doerffel Y. Active Crohn's disease and ulcerative colitis can be specifically diagnosed and monitored based on the biostructure of the fecal flora. Inflamm Bowel Dis. 2008 Feb;14(2):147-61.

Rhodes JM, Robinson R, Beales I, Pugh S, Dickinson R, Dronfield M, Speirs CJ, Wilkinson P, Wilkinson SP. Clinical trial: oral prednisolone metasulfobenzoate (Predocol) vs. oral prednisolone for active ulcerative colitis. Aliment Pharmacol Ther. 2008 Feb 1;27(3):228-40.

Flasar MH, Johnson T, Roghmann MC, Cross RK. Disparities in the use of immunomodulators and biologics for the treatment of inflammatory bowel disease: a retrospective cohort study. Inflamm Bowel Dis. 2008 Jan;14(1):13-9.

Oliveira GR, Teles BC, Brasil EF, Souza MH, Furtado LE, de Castro-Costa CM, Rola FH, Braga LL, Gondim Fde A. Peripheral neuropathy and neurological disorders in an unselected Brazilian population-based cohort of IBD patients. Inflamm Bowel Dis. 2008 Mar;14(3):389-95.

Cappell MS, Turkieh A. Chronic pericarditis and pericardial tamponade associated with ulcerative colitis. Dig Dis Sci. 2008 Jan;53(1):149-54.

Gavalas E, Kountouras J, Stergiopoulos C, Zavos C, Gisakis D, Nikolaidis N, Giouleme O, Chatzopoulos D, Kapetanakis N. Efficacy and safety of infliximab in steroid-dependent ulcerative colitis patients. Hepatogastroenterology. 2007 Jun;54(76):1074-9.

Jones JL, Loftus EV Jr.  Lymphoma risk in inflammatory bowel disease: Is it the disease or its treatment? Inflamm Bowel Dis. 2007 Jun 28

Katsanos KH, Vermeire S, Christodoulou DK, Riis L, Wolters F, Odes S, Freitas J, Hoie O, Beltrami M, Fornaciari G, Clofent J, Bodini P, Vatn M, Nunes PB, Moum B, Munkholm P, Limonard C, Stockbrugger R, Rutgeerts P, Tsianos EV. Dysplasia and Cancer in Inflammatory Bowel Disease 10 Years after Diagnosis: Results of a Population-Based European Collaborative Follow-Up Study.
Digestion. 2007 Jun 26;75(2-3):113-

Cooney RM, Warren BF, Altman DG, Abreu MT, Travis SP.  Outcome measurement in clinical trials for Ulcerative Colitis: towards standardisation. Trials. 2007 Jun 25;8:17.

Lorea Baroja M, Kirjavainen PV, Hekmat S, Reid G.  Anti-inflammatory effects of probiotic yogurt in inflammatory bowel disease patients. Clin Exp Immunol. 2007 Jun 22

Hoie O, Wolters F, Riis L, Aamodt G, Solberg C, Bernklev T, Odes S, Mouzas IA, Beltrami M, Langholz E, Stockbrugger R, Vatn M, Moum B; on behalf of the European Collaborative Study Group of Inflammatory Bowel Disease (EC-IBD).  Ulcerative Colitis: Patient Characteristics May Predict 10-Yr Disease Recurrence in a European-Wide Population-Based Cohort.
Am J Gastroenterol. 2007 Jun 7;

Langhorst J, Mueller T, Luedtke R, Franken U, Paul A, Michalsen A, Schedlowski M, Dobos GJ, Elsenbruch S.  Effects of a comprehensive lifestyle modification program on quality-of-life in patients with ulcerative colitis: a twelve-month follow-up.
Scand J Gastroenterol. 2007 Jun;42(6):734-45

Nuding S, Fellermann K, Wehkamp J, Stange EF.  Reduced mucosal antimicrobial activity in Crohn's disease of the colon.
Gut. 2007 Apr 24;

Ferrante M, Henckaerts L, Joossens M, Pierik M, Joossens S, Dotan N, Norman G, Altstock R, Van Steen K, Rutgeerts P, Van Assche G, Vermeire S.  New serological markers in inflammatory bowel disease are associated with complicated disease behaviour. Gut. 2007 Apr 24;

Yokoyama H, Takagi S, Kuriyama S, Takahashi S, Takahashi H, Iwabuchi M, Takahashi S, Kinouchi Y, Hiwatashi N, Tsuji I, Shimosegawa T.  Effect of weekend 5-aminosalicylic acid (mesalazine) enema as maintenance therapy for ulcerative colitis: Results from a randomized controlled study.
Inflamm Bowel Dis. 2007 Apr 23;

Rubin DT, Rothe JA, Hetzel JT, Cohen RD, Hanauer SB.  Are dysplasia and colorectal cancer endoscopically visible in patients with ulcerative colitis? Gastrointest Endosc. 2007 Jun;65(7):998-1004.  

Scarpa M, van Koperen PJ, Ubbink DT, Hommes DW, Ten Kate FJ, Bemelman WA.  Systematic review of dysplasia after restorative proctocolectomy for ulcerative colitis.
Br J Surg. 2007 May;94(5):534-45.

Jakobovits SL, Jewell DP, Travis SP.  Infliximab for the treatment of ulcerative colitis: outcomes in Oxford from 2000 to 2006.
Aliment Pharmacol Ther. 2007 May 1;25(9):1055-60.

Rodgers AD, Cummins AG.  CRP Correlates with Clinical Score in Ulcerative Colitis but Not in Crohn's Disease.
Dig Dis Sci. 2007 Apr 11;

Turk N, Kastelan D, Cukovic-Cavka S, Kraljevic I, Korsic M, Vucelic B.  Discriminatory ability of calcaneal quantitative ultrasound in the assessment of bone status in patients with inflammatory bowel disease. Ultrasound Med Biol. 2007 Jun;33(6):863-9.

Rahimi R, Nikfar S, Rezaie A, Abdollahi M.  A Meta-Analysis of Antibiotic Therapy for Active Ulcerative Colitis.
Dig Dis Sci. 2007 Apr 6;

McHugh JB, Appelman HD, McKenna BJ.  The diagnostic value of endoscopic terminal ileum biopsies. Am J Gastroenterol. 2007 May;102(5):1084-9.

Bortoli A, Saibeni S, Tatarella M, Prada A, Beretta L, Rivolta R, Politi P, Ravelli P, Imperiali G, Colombo E, Pera A, Daperno M, Carnovali M, de Franchis R, Vecchi M; the Study Group for Inflammatory Bowel Diseases GSMII. Angriman I, Scarpa M, D'Inca R, Basso D, Ruffolo C, Polese L, Sturniolo GC, D'Amico DF, Plebani M.  Enzymes in feces: useful markers of chronic inflammatory bowel disease.
Clin Chim Acta. 2007 May;381(1):63-8.

de Bievre MA, Vrij AA, Schoon EJ, Dijkstra G, de Jong AE, Oberndorff-Klein Woolthuis AH, Hemker HC, Stockbrugger RW. Randomized, placebo-controlled trial of low molecular weight heparin in active ulcerative colitis. Inflamm Bowel Dis. 2007 Jun;13(6):753-8.

Jess T, Riis L, Vind I, Winther KV, Borg S, Binder V, Langholz E, Thomsen OO, Munkholm P.  Changes in clinical characteristics, course, and prognosis of inflammatory bowel disease during the last 5 decades: a population-based study from Copenhagen, Denmark. Inflamm Bowel Dis. 2007 Apr;13(4):481-9.

Terdiman JP, Steinbuch M, Blumentals WA, Ullman TA, Rubin DT.  5-Aminosalicylic acid therapy and the risk of colorectal cancer among patients with inflammatory bowel disease. Inflamm Bowel Dis. 2007 Apr;13(4):367-71.

Cornish J, Tan E, Teare J, Teoh TG, Rai R, Clark SK, Tekkis PP.  A meta-analysis on the influence of inflammatory bowel disease on pregnancy. Gut. 2007 Jun;56(6):830-7. Epub 2006 Dec 21.

Jiang L, Xia B, Li J, Ye M, Deng C, Ding Y, Luo H, Ren H, Hou X, Liu H, Xu H, Cheng H, Yang H. Risk factors for ulcerative colitis in a Chinese population: an age-matched and sex-matched case-control study.
J Clin Gastroenterol. 2007 Mar;41(3):280-4.

Meisner RS, Spier BJ, Einarsson S, Roberson EN, Perlman SB, Bianco JA, Taylor AJ, Einstein M, Jaskowiak CJ, Massoth KM, Reichelderfer M. Pilot study using PET/CT as a novel, noninvasive assessment of disease activity in inflammatory bowel disease. Inflamm Bowel Dis. 2007 Mar 29;

McHugh JB, Appelman HD, McKenna BJ. The Diagnostic Value of Endoscopic Terminal Ileum Biopsies.
Am J Gastroenterol. 2007 Mar 27;

Bresci G, Parisi G, Mazzoni A, Scatena F, Capria A. Treatment of patients with acute ulcerative colitis: Conventional corticosteroid therapy (MP) versus granulocytapheresis (GMA): A pilot study.
Dig Liver Dis. 2007 May;39(5):430-4.  

Takemoto K, Kato J, Kuriyama M, Nawa T, Kurome M, Okada H, Sakaguchi K, Shiratori Y.Predictive factors of efficacy of leukocytapheresis for steroid-resistant ulcerative colitis patients. Dig Liver Dis. 2007 May;39(5):422-9.

Hookey LC, Hurlbut DJ, Day AG, Manley PN, Depew WT. One bite or two? A prospective trial comparing colonoscopy biopsy technique in patients with chronic ulcerative colitis. Can J Gastroenterol. 2007 Mar;21(3):164-8.

Angriman I, Scarpa M, D'Inca R, Basso D, Ruffolo C, Polese L, Sturniolo GC, D'Amico DF, Plebani M. Enzymes in feces: Useful markers of chronic inflammatory bowel disease.
Clin Chim Acta. 2007 Feb 21;

Komanduri S, Gillevet PM, Sikaroodi M, Mutlu E, Keshavarzian A. Dysbiosis in pouchitis: evidence of unique microfloral patterns in pouch inflammation.
Clin Gastroenterol Hepatol. 2007 Mar;5(3):352-60.

Biancone L, Gionchetti P, Blanco Gdel V, Orlando A, Annese V, Papi C, Sostegni R, D'Inca R, Petruzziello C, Casa A, Sica G, Calabrese E, Campieri M, Pallone F. Beclomethasone dipropionate versus mesalazine in distal ulcerative colitis: A multicenter, randomized, double-blind study. Dig Liver Dis. 2007 Apr;39(4):329-37.

Tuvlin JA, Raza SS, Bracamonte S, Julian C, Hanauer SB, Nicolae DL, King AC, Cho JH. Smoking and inflammatory bowel disease: Trends in familial and sporadic cohorts.
Inflamm Bowel Dis. 2007 Mar 7;13(5):573-579

Aldhous MC, Drummond HE, Anderson N, Baneshi MR, Smith LA, Arnott ID, Satsangi J. Smoking habit and load influence age at diagnosis and disease extent in ulcerative colitis. Am J Gastroenterol. 2007 Mar;102(3):589-97.

Miki C, Ohmori Y, Yoshiyama S, Toiyama Y, Araki T, Uchida K, Kusunoki M. Factors predicting postoperative infectious complications and early induction of inflammatory mediators in ulcerative colitis patients.
World J Surg. 2007 Mar;31(3):522-9.

Strober W, Fuss I, Mannon P. The fundamental basis of inflammatory bowel disease. J Clin Invest. 2007 Mar;117(3):514-21. Review.

Ljung T, Thomsen OO, Vatn M, Karlen P, Karlsen LN, Tysk C, Nilsson SU, Kilander A, Gillberg R, Grip O, Lindgren S, Befrits R, Lofberg R. Granulocyte, monocyte/macrophage apheresis for inflammatory bowel disease: the first 100 patients treated in Scandinavia. Scand J Gastroenterol. 2007 Feb;42(2):221-7.

Feagan BG, Reinisch W, Rutgeerts P, Sandborn WJ, Yan S, Eisenberg D, Bala M, Johanns J, Olson A, Hanauer SB. The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients. Am J Gastroenterol. 2007 Apr;102(4):794-802.

Yantiss RK, Odze RD. Pitfalls in the interpretation of nonneoplastic mucosal biopsies in inflammatory bowel disease. Am J Gastroenterol. 2007 Apr;102(4):890-904

Thomas T, Abrams KA, Robinson RJ, Mayberry JF. Meta-analysis: cancer risk of low-grade dysplasia in chronic ulcerative colitis. Aliment Pharmacol Ther. 2007 Mar 15;25(6):657-68.

Subramanian V, Banerjee A, Beharry N, Farthing MJ, Pollok RC. Determining the proximal extent of ulcerative colitis: white cell scan correlates well with histological assessment. Aliment Pharmacol Ther. 2007 Feb 15;25(4):441-6.

de Bievre MA, Vrij AA, Schoon EJ, Dijkstra G, de Jong AE, Oberndorff-Klein Woolthuis AH, Hemker HC, Stockbrugger RW. Randomized, placebo-controlled trial of low molecular weight heparin in active ulcerative colitis.
Inflamm Bowel Dis. 2007 Jan 26;13(6):753-758

Su C, Lewis JD, Goldberg B, Brensinger C, Lichtenstein GR. A meta-analysis of the placebo rates of remission and response in clinical trials of active ulcerative colitis. Gastroenterology. 2007 Feb;132(2):516-26.  

Timmer A, McDonald JW, Macdonald JK. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2007 Jan 24;(1):CD000478. Review.

Gisbert JP, Gonzalez-Lama Y, Mate J. Systematic review: Infliximab therapy in ulcerative colitis. Aliment Pharmacol Ther. 2007 Jan 1;25(1):19-37.

Ng SC, Arebi N, Kamm MA. Medium-term results of oral tacrolimus treatment in refractory inflammatory bowel disease. Inflamm Bowel Dis. 2007 Feb;13(2):129-34.

Menees S, Higgins P, Korsnes S, Elta G. Does colonoscopy cause increased ulcerative colitis symptoms? Inflamm Bowel Dis. 2007 Jan;13(1):12-8.

Masunaga Y, Ohno K, Ogawa R, Hashiguchi M, Echizen H, Ogata H. Meta-analysis of risk of malignancy with immunosuppressive drugs in inflammatory bowel disease. Ann Pharmacother. 2007 Jan;41(1):21-8.

Makharia GK, Sachdev V, Gupta R, Lal S, Pandey RM. Anti-Saccharomyces cerevisiae antibody does not differentiate between Crohn's disease and intestinal tuberculosis. Dig Dis Sci. 2007 Jan;52(1):33-9.

Jess T, Gamborg M, Munkholm P, Sorensen TI. Overall and cause-specific mortality in ulcerative colitis: meta-analysis of population-based inception cohort studies.
Am J Gastroenterol. 2007 Mar;102(3):609-17.

Bossa F, Fiorella S, Caruso N, Accadia L, Napolitano G, Valvano MR, Andriulli A, Annese V. Continuous infusion versus bolus administration of steroids in severe attacks of ulcerative colitis: a randomized, double-blind trial.
Am J Gastroenterol. 2007 Mar;102(3):601-8.

Turner D, Walsh CM, Steinhart AH, Griffiths AM. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol. 2007 Jan;5(1):103-10.

Brunner B, Scheurer U, Seibold F. Differences in yeast intolerance between patients with Crohn's disease and ulcerative colitis. Dis Colon Rectum. 2007 Jan;50(1):83-8.

Castro M, Papadatou B, Ceriati E, Knafelz D, De Angelis P, Ferretti F, Gambarara M, Diamanti A, De Peppo F, Rivosecchi M. Role of cyclosporin in preventing or delaying colectomy in children with severe ulcerative colitis. Langenbecks Arch Surg. 2007 Mar;392(2):161-4.

Su C, Lewis JD, Goldberg B, Brensinger C, Lichtenstein GR. A Meta-Analysis of the Placebo Rates of Remission and Response in Clinical Trials of Active Ulcerative Colitis. Gastroenterology. 2006 Dec 20;

Familiari L, Strangio G, Consolo P, Luigiano C, Bonica M, Barresi G, Barresi V, Familiari P, D'Arrigo G, Alibrandi A, Zirilli A, Fries W, Scaffidi M. Optical coherence tomography evaluation of ulcerative colitis: the patterns and the comparison with histology.
Am J Gastroenterol. 2006 Dec;101(12):2833-40.

Jess T, Riis L, Vind I, Winther KV, Borg S, Binder V, Langholz E, Thomsen OO, Munkholm P. Changes in clinical characteristics, course, and prognosis of inflammatory bowel disease during the last 5 decades: A population-based study from Copenhagen, Denmark. Inflamm Bowel Dis. 2006 Dec 19;

Ferrante M, Vermeire S, Katsanos KH, Noman M, Van Assche G, Schnitzler F, Arijs I, De Hertogh G, Hoffman I, Geboes K, Rutgeerts P. Predictors of early response to infliximab in patients with ulcerative colitis. Inflamm Bowel Dis. 2006 Dec 19;

Cornish JA, Tan EK, Teare J, Teoh TG, Rai R, Clark SK, Tekkis PP. A Meta-analysis on the Influence of Inflammatory Bowel Disease on Pregnancy. Gut. 2006 Dec 21; [

Jess T, Gamborg M, Munkholm P, Sorensen TI. Overall and Cause-Specific Mortality in Ulcerative Colitis: Meta-analysis of Population-Based Inception Cohort Studies. Am J Gastroenterol. 2006 Dec 11;

Bossa F, Fiorella S, Caruso N, Accadia L, Napolitano G, Valvano MR, Andriulli A, Annese V. Continuous Infusion Versus Bolus Administration of Steroids in Severe Attacks of Ulcerative Colitis: A Randomized, Double-Blind Trial. Am J Gastroenterol. 2006 Dec 11;

Sood A, Midha V, Sood N, Bansal M. Long term results of use of azathioprine in patients with ulcerative colitis in India.
World J Gastroenterol. 2006 Dec 7;12(45):7332-6.

Turner D, Walsh CM, Steinhart AH, Griffiths AM. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol. 2007 Jan;5(1):103-10.

Ha JS, Lee JS, Kim HJ, Moon TG, Chang DK, Lee JH, Kim YH, Rhee PL, Kim JJ, Rhee JC. Comparative usefulness of erythrocyte sedimentation rate and C-reactive protein in assessing the severity of ulcerative colitis] Korean J Gastroenterol. 2006 Nov;48(5):313-20.

Vergara T, Cofre P, Cifuentes S, Pulgar U, Puebla C, Velasco S. [Presence of antineutrophil cytoplasmic antibodies (ANCA) and anti Saccharomyces cerevisiae antibodies (ASCA) among patients with ulcerative colitis] Rev Med Chil. 2006 Aug;134(8):960-4.

Mahid SS, Minor KS, Soto RE, Hornung CA, Galandiuk S. Smoking and inflammatory bowel disease: a meta-analysis. Mayo Clin Proc. 2006 Nov;81(11):1462-71.

Weber A, Fein F, Koch S, Dupont-Gossart AC, Mantion G, Heyd B, Carbonnel F. Treatment of ulcerative colitis refractory to steroid therapy by oral microemulsion cyclosporine (Neoral).
Inflamm Bowel Dis. 2006 Dec;12(12):1131-5.

Loftus EV Jr. A practical perspective on ulcerative colitis: patients' needs from aminosalicylate therapies. Inflamm Bowel Dis. 2006 Dec;12(12):1107-13.

Lerebours E, Gower-Rousseau C, Merle V, Brazier F, Debeugny S, Marti R, Salomez JL, Hellot MF, Dupas JL, Colombel JF, Cortot A, Benichou J. Stressful Life Events as a Risk Factor for Inflammatory Bowel Disease Onset: A Population-Based Case-Control Study.
Am J Gastroenterol. 2006 Nov 13;

Chung GE, Cheon JH, Lee JY, Ye BD, Kim SG, Kim JS, Jung HC, Song IS.[Efficacy of combination of intravenous cyclosporin A and steroid therapy versus prolonged intravenous steroid therapy alone in patients with severe ulcerative colitis refractory to initial intravenous steroid therapy] Korean J Gastroenterol. 2006 Oct;48(4):263-8.

Rubin DT, LoSavio A, Yadron N, Huo D, Hanauer SB. Aminosalicylate therapy in the prevention of dysplasia and colorectal cancer in ulcerative colitis. Clin Gastroenterol Hepatol. 2006 Nov;4(11):1346-50.

Hoie O, Schouten L, Wolters F, Solberg C, Riis L, Mouzas I, Politi P, Odes S, Langholz E, Vatn M, Stockbrugger R, Moum B. Ulcerative colitis: no rise in mortality in a European-wide population-based cohort 10 years after diagnosis.
Gut. 2006 Oct 6;

Regueiro M, Loftus EV Jr, Steinhart AH, Cohen RD. Medical management of left-sided ulcerative colitis and ulcerative proctitis: critical evaluation of therapeutic trials. Inflamm Bowel Dis. 2006 Oct;12(10):979-94.

Regueiro M, Loftus EV Jr, Steinhart AH, Cohen RD. Clinical guidelines for the medical management of left-sided ulcerative colitis and ulcerative proctitis: summary statement.
Inflamm Bowel Dis. 2006 Oct;12(10):972-8.

Hanauer SB. Review article: high-dose aminosalicylates to induce and maintain remissions in ulcerative colitis.
Aliment Pharmacol Ther. 2006 Oct;24 Suppl 3:37-40.

Waljee A, Waljee J, Morris AM, Higgins PD. Threefold increased risk of infertility: a meta-analysis of infertility after ileal pouch anal anastomosis in ulcerative colitis. Gut. 2006 Nov;55(11):1575-80.

Ding YJ, Yu JP, Luo HS, Zhou ZY, Liu J. Evaluation and analysis of colonoscopy in the diagnosis of 186 cases of ulcerative colitis patients. Int J Clin Pract. 2006 Nov;60(11):1408-10.

Ikeuchi H, Hori K, Nishigami T, Nakano H, Uchino M, Nakamura M, Kaibe N, Noda M, Yanagi H, Yamamura T. Diffuse gastroduodenitis and pouchitis associated with ulcerative colitis. World J Gastroenterol. 2006 Sep 28;12(36):5913-5.

Okada H, Makidono C, Takenaka R, Hiraoka S, Fujiwara A, Kato J, Kawahara Y, Kawamoto H, Mizuno M, Shiratori Y. Therapeutic Efficacy of Leukocytapheresis in a Pregnant Woman with Severe Active Ulcerative Colitis. Digestion. 2006 Aug 29;74(1):15-18

Sands BE, Kilgore KM, Bloomfeld RS, Sandborn WJ. Variation in severity assessment and initial mesalamine dose selection for ulcerative colitis in community practice. J Clin Gastroenterol. 2006 Aug;40(7):587-91.

Mawdsley JE, Macey MG, Feakins RM, Langmead L, Rampton DS. The effect of acute psychologic stress on systemic and rectal mucosal measures of inflammation in ulcerative colitis. Gastroenterology. 2006 Aug;131(2):410-9.

Bernal I, Manosa M, Domenech E, Garcia-Planella E, Navarro M, Lorenzo-Zuniga V, Cabre E, Gassull MA. Predictors of clinical response to systemic steroids in active ulcerative colitis.
Dig Dis Sci. 2006 Aug;51(8):1434-8.

Kornbluth A, Hayes M, Feldman S, Hunt M, Fried-Boxt E, Lichtiger S, Legnani P, George J, Young J. Do guidelines matter? Implementation of the ACG and AGA osteoporosis screening guidelines in inflammatory bowel disease (IBD) patients who meet the guidelines' criteria. Am J Gastroenterol. 2006 Jul;101(7):1546-50.

Riis L, Vind I, Politi P, Wolters F, Vermeire S, Tsianos E, Freitas J, Mouzas I, Ruiz Ochoa V, O'Morain C, Odes S, Binder V, Moum B, Stockbrugger R, Langholz E, Munkholm P; European Collaborative study group on Inflammatory Bowel Disease. Does pregnancy change the disease course? A study in a European cohort of patients with inflammatory bowel disease. Am J Gastroenterol. 2006 Jul;101(7):1539-45.

Bibiloni R, Mangold M, Madsen KL, Fedorak RN, Tannock GW. The bacteriology of biopsies differs between newly diagnosed, untreated, Crohn's disease and ulcerative colitis patients. J Med Microbiol. 2006 Aug;55(Pt 8):1141-9.

Ho GT, Chiam P, Drummond H, Loane J, Arnott ID, Satsangi J. The efficacy of corticosteroid therapy in inflammatory bowel disease: analysis of a 5-year UK inception cohort. Aliment Pharmacol Ther. 2006 Jul 15;24(2):319-30.

Zilberman L, Maharshak N, Arbel Y, Rogowski O, Rozenblat M, Shapira I, Berliner S, Arber N, Dotan I. Correlated expression of high-sensitivity C-reactive protein in relation to disease activity in inflammatory bowel disease: lack of differences between Crohn's disease and ulcerative colitis. Digestion. 2006;73(4):205-9.

Arseneau KO, Sultan S, Provenzale DT, Onken J, Bickston SJ, Foley E, Connors AF Jr, Cominelli F. Do patient preferences influence decisions on treatment for patients with steroid-refractory ulcerative colitis? Clin Gastroenterol Hepatol. 2006 Sep;4(9):1135-42.

Regueiro M, Curtis J, Plevy S. Infliximab for hospitalized patients with severe ulcerative colitis. J Clin Gastroenterol. 2006 Jul;40(6):476-81.

Henriksen M, Jahnsen J, Lygren I, Sauar J, Kjellevold O, Schulz T, Vatn MH, Moum B; IBSEN Study Group. Ulcerative colitis and clinical course: results of a 5-year population-based follow-up study (the IBSEN study). Inflamm Bowel Dis. 2006 Jul;12(7):543-50.

Picco MF, Krishna M, Cangemi JR, Shelton D. Oral mesalamine and clinical remission are associated with a decrease in the extent of long-standing ulcerative colitis. Inflamm Bowel Dis. 2006 Jul;12(7):537-42.

Rutter MD, Saunders BP, Wilkinson KH, Schofield G, Forbes A. Intangible costs and benefits of ulcerative colitis surveillance: a patient survey. Dis Colon Rectum. 2006 Aug;49(8):1177-83.

Wolters FL, Russel MG, Sijbrandij J, Schouten LJ, Odes S, Riis L, Munkholm P, Langholz E, Bodini P, O'morain C, Katsanos K, Tsianos E, Vermeire S, Van Zeijl G, Limonard C, Hoie O, Vatn M, Moum B, W Stockbrugger R, On Behalf Of The European Collaborative Study Group On Inflammatory Bowel Disease Ec-Ibd. Disease outcome of inflammatory bowel disease patients: General outline of a Europe-wide population-based 10-year clinical follow-up study. Scand J Gastroenterol Suppl. 2006 May;(243):46-54. 

Siegel CA, Sands BE. Risk factors for colorectal cancer in Crohn's colitis: a case-control study. Inflamm Bowel Dis. 2006 Jun;12(6):491-6. 

Halme L, Paavola-Sakki P, Turunen U, Lappalainen M, Farkkila M, Kontula K. Family and twin studies in inflammatory bowel disease. World J Gastroenterol. 2006 Jun 21;12(23):3668-72.  

Vind I, Riis L, Jess T, Knudsen E, Pedersen N, Elkjaer M, Bak Andersen I, Wewer V, Norregaard P, Moesgaard F, Bendtsen F, Munkholm P; the DCCD study group. Increasing incidences of inflammatory bowel disease and decreasing surgery rates in Copenhagen City and County, 2003-2005: a population-based study from the Danish Crohn colitis database. Am J Gastroenterol. 2006 Jun;101(6):1274-82. 

Fallingborg JF.  [Does 5-ASA prevent development of colon cancer in ulcerative colitis?] Ugeskr Laeger. 2006 May 22;168(21):2049-51. Review. Danish.  

Ochsenkuhn T, Tillack C, Stepp H, Diebold J, Ott SJ, Baumgartner R, Brand S, Goke B, Sackmann M. Low frequency of colorectal dysplasia in patients with long-standing inflammatory bowel disease colitis: detection by fluorescence endoscopy.
Endoscopy. 2006 May;38(5):477-82.  

Danese S, Sans M, de la Motte C, Graziani C, West G, Phillips MH, Pola R, Rutella S, Willis J, Gasbarrini A, Fiocchi C.  Angiogenesis as a novel component of inflammatory bowel disease pathogenesis. Gastroenterology. 2006 Jun;130(7):2060-73.

Velayos FS, Loftus EV Jr, Jess T, Harmsen WS, Bida J, Zinsmeister AR, Tremaine WJ, Sandborn WJ. Predictive and protective factors associated with colorectal cancer in ulcerative colitis: A case-control study. Gastroenterology. 2006 Jun;130(7):1941-9.  

Jaskowski TD, Litwin CM, Hill HR. Analysis of serum antibodies in patients suspected of having inflammatory bowel disease.
Clin Vaccine Immunol. 2006 Jun;13(6):655-60.   

Ljung T, Lundberg S, Varsanyi M, Johansson C, Schmidt PT, Herulf M, Lundberg JO, Hellstrom PM. Rectal nitric oxide as biomarker in the treatment of inflammatory bowel disease: responders versus nonresponders. World J Gastroenterol. 2006 Jun 7;12(21):3386-92.  

Gionchetti P, Rizzello F, Lammers KM, Morselli C, Sollazzi L, Davies S, Tambasco R, Calabrese C, Campieri M. Antibiotics and probiotics in treatment of inflammatory bowel disease. World J Gastroenterol. 2006 Jun 7;12(21):3306-13. 

Jacobsen BA, Fallingborg J, Rasmussen HH, Nielsen KR, Drewes AM, Puho E, Nielsen GL, Sorensen HT. Increase in incidence and prevalence of inflammatory bowel disease in northern Denmark: a population-based study, 1978-2002. Eur J Gastroenterol Hepatol. 2006 Jun;18(6):601-6. 

Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006 Jun;55(6):749-53. 

Zocco MA, dal Verme LZ, Cremonini F, Piscaglia AC, Nista EC, Candelli M, Novi M, Rigante D, Cazzato IA, Ojetti V, Armuzzi A, Gasbarrini G, Gasbarrini A. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther. 2006 Jun 1;23(11):1567-74.  

Nguyen GC, Torres EA, Regueiro M, Bromfield G, Bitton A, Stempak J, Dassopoulos T, Schumm P, Gregory FJ, Griffiths AM, Hanauer SB, Hanson J, Harris ML, Kane SV, Orkwis HK, Lahaie R, Oliva-Hemker M, Pare P, Wild GE, Rioux JD, Yang H, Duerr RH, Cho JH, Steinhart AH, Brant SR, Silverberg MS. Inflammatory bowel disease characteristics among African Americans, Hispanics, and non-Hispanic Whites: characterization of a large North American cohort. Am J Gastroenterol. 2006 May;101(5):1012-23.

Bernstein CN, Rawsthorne P, Cheang M, Blanchard JF. A population-based case control study of potential risk factors for IBD. Am J Gastroenterol. 2006 May;101(5):993-1002.  

Creed TJ, Probert CS, Norman MN, Moorghen M, Shepherd NA, Hearing SD, Dayan CM; BASBUC INVESTIGATORS. Basiliximab for the treatment of steroid-resistant ulcerative colitis: further experience in moderate and severe disease. Aliment Pharmacol Ther. 2006 May 15;23(10):1435-42.  

Miner PB Jr, Wedel MK, Xia S, Baker BF. Safety and efficacy of two dose formulations of alicaforsen enema compared with mesalazine enema for treatment of mild to moderate left-sided ulcerative colitis: a randomized, double-blind, active-controlled trial. Aliment Pharmacol Ther. 2006 May 15;23(10):1403-13.  

Sutherland L, Macdonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2006 Apr 19;(2):CD000544. Review 

Sutherland L, Macdonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
Cochrane Database Syst Rev. 2006 Apr 19;(2):CD000543. Review.

Jess T, Loftus EV Jr, Velayos FS, Harmsen WS, Zinsmeister AR, Smyrk TC, Schleck CD, Tremaine WJ, Melton LJ 3rd, Munkholm P, Sandborn WJ. Risk of intestinal cancer in inflammatory bowel disease: a population-based study from olmsted county, Minnesota. Gastroenterology. 2006 Apr;130(4):1039-46.  

Giampaolo B, Giuseppe P, Michele B, Alessandro M, Fabrizio S, Alfonso C. Treatment of active steroid-refractory inflammatory bowel diseases with granulocytapheresis: Our experience with a prospective study. World J Gastroenterol. 2006 Apr 14;12(14):2201-4. 

Van Assche G, Sandborn WJ, Feagan BG, Salzberg B, Silvers D, Monroe P, Pandak WM, Anderson FH, Valentine JF, Wild GE, Geenen DJ, Sprague R, Targan SR, Rutgeerts PJ, Vexler V, Young D, Shames RS. Daclizumab, a humanized monoclonal antibody to the interleukin-2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double-blind, placebo-controlled, dose- ranging trial. Gut. 2006 Apr 7;   

Bergman R, Parkes M. Systematic review: the use of mesalazine in inflammatory bowel disease. Aliment Pharmacol Ther. 2006 Apr 1;23(7):841-55. 

Baumgart DC, Pintoffl JP, Sturm A, Wiedenmann B, Dignass AU. Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease--a long-term follow-up. Am J Gastroenterol. 2006 May;101(5):1048-56.  
Aratari A, Papi C, Galletti B, Angelucci E, Viscido A, D'Ovidio V, Ciaco A, Abdullahi M, Caprilli R. Seasonal variations in onset of symptoms in Crohn's disease. Dig Liver Dis. 2006 May;38(5):319-23.

Sincic BM, Vucelic B, Persic M, Brncic N, Erzen DJ, Radakovic B, Micovic V, Stimac D. Incidence of inflammatory bowel disease in Primorsko-goranska County, Croatia, 2000-2004: A prospective population-based study. Scand J Gastroenterol. 2006 Mar;41(4):437-444.

Floch MH, Madsen KK, Jenkins DJ, Guandalini S, Katz JA, Onderdonk A, Walker WA, Fedorak RN, Camilleri M. Recommendations for Probiotic Use. J Clin Gastroenterol. 2006 Mar;40(3):275-278.

Baumgart DC, Pintoffl JP, Sturm A, Wiedenmann B, Dignass AU. Tacrolimus Is Safe and Effective in Patients with Severe Steroid-Refractory or Steroid-Dependent Inflammatory Bowel Disease-A Long-Term Follow-Up. Am J Gastroenterol. 2006 Mar 30;

Sawada K, Takahashi R, Saniabadi AR, Ohdo M, Shimoyama T. Elevated plasma cryofibrinogen in patients with active inflammatory bowel disease is morbigenous. World J Gastroenterol. 2006 Mar 14;12(10):1621-5.

Ansari N, Abdulla J, Zayyani N, Brahmi U, Taha S, Abdel Satir A. Comparison of RANTES expression in Crohn's disease and ulcerative colitis: an aid in the differential diagnosis? J Clin Pathol. 2006 Mar 24;

Jang JY, Kim HJ, Jung JH, Chae MJ, Kim NH, Lee SK, Joo KR, Dong SH, Kim BH, Chang YW, Lee JI, Chang R.  [The role of smoking as a risk factor in inflammatory bowel diseases: single center study in Korea] Korean J Gastroenterol. 2006 Mar;47(3):198-204. Korean.

Barta Z, Toth L, Zeher M. Pulse cyclophosphamide therapy for inflammatory bowel disease. World J Gastroenterol. 2006 Feb 28;12(8):1278-80.

Kiehne K, Brunke G, Wegner F, Banasiewicz T, Folsch UR, Herzig KH. Defensin expression in chronic pouchitis in patients with ulcerative colitis or familial adenomatous polyposis coli. World J Gastroenterol. 2006 Feb 21;12(7):1056-62.

Bai AP, Ouyang Q, Xiao XR, Li SF. Probiotics modulate inflammatory cytokine secretion from inflamed mucosa in active ulcerative colitis. Int J Clin Pract. 2006 Mar;60(3):284-8.

Annese V, Latiano A, Palmieri O, Lombardi G, Andriulli A; Italian Group of Inflammatory Bowel Disease. NOD2/CARD15 in healthy relatives of IBD patients. Eur Rev Med Pharmacol Sci. 2006 Jan-Feb;10(1):33-6.

Ogata H, Matsui T, Nakamura M, Iida M, Takazoe M, Suzuki Y, Hibi T. A randomised, dose-finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut. 2006 Feb 16;

Mallant-Hent RC, Mooij M, von Blomberg BM, Linskens RK, van Bodegraven AA, Savelkoul PH. Correlation between Saccharomyces cerevisiae DNA in intestinal mucosal samples and anti-Saccharomyces cerevisiae antibodies in serum of patients with IBD. World J Gastroenterol. 2006 Jan 14;12(2):292-7.

Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut. 2006 Mar;55(3):426-31. Review.

Sandborn WJ, Stenson WF, Brynskov J, Lorenz RG, Steidle GM, Robbins JL, Kent JD, Bloom BJ. Safety of celecoxib in patients with ulcerative colitis in remission: a randomized, placebo-controlled, pilot study. Clin Gastroenterol Hepatol. 2006 Feb;4(2):203-11.

Takeuchi K, Smale S, Premchand P, Maiden L, Sherwood R, Thjodleifsson B, Bjornsson E, Bjarnason I. Prevalence and mechanism of nonsteroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease.
Clin Gastroenterol Hepatol. 2006 Feb;4(2):196-202.

Mawdsley JE, Irving PM, Makins RJ, Rampton DS. Optimizing quality of outpatient care for patients with inflammatory bowel disease: the importance of specialist clinics. Eur J Gastroenterol Hepatol. 2006 Mar;18(3):249-53.

El Miedany Y, Youssef S, Ahmed I, El Gaafary M. The gastrointestinal safety and effect on disease activity of etoricoxib, a selective cox-2 inhibitor in inflammatory bowel diseases. Am J Gastroenterol. 2006 Feb;101(2):311-7.

M'koma AE. Serum biochemical evaluation of patients with functional pouches ten to 20 years after restorative proctocolectomy. Int J Colorectal Dis. 2006 Jan 26;:1-10

Burczynski ME, Peterson RL, Twine NC, Zuberek KA, Brodeur BJ, Casciotti L, Maganti V, Reddy PS, Strahs A, Immermann F, Spinelli W, Schwertschlag U, Slager AM, Cotreau MM, Dorner AJ. Molecular classification of Crohn's disease and ulcerative colitis patients using transcriptional profiles in peripheral blood mononuclear cells. J Mol Diagn. 2006 Feb;8(1):51-61.

Jess T, Loftus Jr EV, Harmsen WS, Zinsmeister AR, Tremaine WJ, Melton LJ, Munkholm P, Sandborn WJ. Survival and cause-specific mortality in patients with inflammatory bowel disease: a long-term outcome study in Olmsted County, Minnesota, 1940-2004. Gut. 2006 Jan 19;

Bernstein CN, Nabalamba A. Hospitalization, surgery, and readmission rates of IBD in Canada: a population-based study. Am J Gastroenterol. 2006 Jan;101(1):110-8.

Kuehbacher T, Ott SJ, Helwig U, Mimura T, Rizzello F, Kleessen B, Gionchetti P, Blaut M, Campieri M, Folsch UR, Kamm MA, Schreiber S. Bacterial and fungal microbiota in relation to probiotic therapy (VSL#3) in pouchitis. Gut. 2006 Jan 9;

Ardizzone S, Maconi G, Russo A, Imbesi V, Colombo E, Bianchi Porro G. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut. 2006 Jan;55(1):47-53.

Makiyama K, Takeshima F, Hamamoto T. Efficacy of rebamipide enemas in active distal ulcerative colitis and proctitis: a prospective study report. Dig Dis Sci. 2005 Dec;50(12):2323-9.  

Preda CM, Vermeire S, Rutgeerts P, Joosens S, Diculescu M, Marica C, Ciocarlan M, Mirea V, Oproiu A. Prevalence and significance of perinuclear anti-neutrophil antibodies (pANCA) in Romanian patients with Crohn's disease and ulcerative colitis.
Rom J Gastroenterol. 2005 Dec;14(4):357-60.  

Garcia-Lopez S, Gomollon-Garcia F, Perez-Gisbert J. Cyclosporine in the treatment of severe attack of ulcerative colitis: a systematic review. Gastroenterol Hepatol. 2005 Dec;28(10):607-614.  

Glas J, Torok HP, Daczo J, Tonenchi L, Folwaczny M, Folwaczny C. The leukocyte count predicts the efficacy of treatment with azathioprine in inflammatory bowel disease. Eur J Med Res. 2005 Dec 7;10(12):535-8. 

Thomas GA, Rhodes J, Ingram JR. Mechanisms of disease: nicotine--a review of its actions in the context of gastrointestinal disease. Nat Clin Pract Gastroenterol Hepatol. 2005 Nov;2(11):536-44.   

Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF. Infliximab for induction and maintenance therapy for ulcerative colitis.
N Engl J Med. 2005 Dec 8;353(23):2462-76. 

Ohkusa T, Nomura T, Terai T, Miwa H, Kobayashi O, Hojo M, Takei Y, Ogihara T, Hirai S, Okayasu I, Sato N. Effectiveness of antibiotic combination therapy in patients with active ulcerative colitis: a randomized, controlled pilot trial with long-term follow-up.
Scand J Gastroenterol. 2005 Nov;40(11):1334-42.  

Vermeire S, Van Assche G, Rutgeerts P. The role of C-reactive protein as an inflammatory marker in gastrointestinal diseases.
Nat Clin Pract Gastroenterol Hepatol. 2005 Dec;2(12):580-6.  

Aleksandra Nielsen A, Nederby Nielsen J, Schmedes A, Brandslund I, Hey H. Saliva Interleukin-6 in patients with inflammatory bowel disease. Scand J Gastroenterol. 2005 Dec;40(12):1444-8. 

Ingram JR, Rhodes J, Evans BK, Thomas GA. Preliminary observations of oral nicotine therapy for inflammatory bowel disease: an open-label phase I-II study of tolerance.
Inflamm Bowel Dis. 2005 Dec;11(12):1092-6.  

de Silva AD, Tsironi E, Feakins RM, Rampton DS. Efficacy and tolerability of oral iron therapy in inflammatory bowel disease: a prospective, comparative trial. Aliment Pharmacol Ther. 2005 Dec;22(11-12):1097-105. 

Hurlstone DP, Sanders DS, Lobo AJ, McAlindon ME, Cross SS. Prospective evaluation of high-frequency mini-probe ultrasound colonoscopic imaging in ulcerative colitis: a valid tool for predicting clinical severity. Eur J Gastroenterol Hepatol. 2005 Dec;17(12):1325-31. 

Staib F, Robles AI, Varticovski L, Wang XW, Zeeberg BR, Sirotin M, Zhurkin VB, Hofseth LJ, Hussain SP, Weinstein JN, Galle PR, Harris CC. The p53 tumor suppressor network is a key responder to microenvironmental components of chronic inflammatory stress.
Cancer Res. 2005 Nov 15;65(22):10255-64.  

Colliver DW, Crawford NP, Eichenberger MR, Zacharius W, Petras RE, Stromberg AJ, Galandiuk S. Molecular profiling of ulcerative colitis-associated neoplastic progression. Exp Mol Pathol. 2006 Feb;80(1):1-10. 

Buckland MS, Mylonaki M, Rampton D, Longhurst HJ. Serological markers (anti-Saccharomyces cerevisiae mannan antibodies and antineutrophil cytoplasmic antibodies) in inflammatory bowel disease: diagnostic utility and phenotypic correlation.
Clin Diagn Lab Immunol. 2005 Nov;12(11):1328-30.  

Kratzer W, Haenle MM, Mason RA, von Tirpitz C, Kaechele V. Prevalence of cholelithiasis in patients with chronic inflammatory bowel disease. World J Gastroenterol. 2005 Oct 21;11(39):6170-5.  

Ingram JR, Thomas GA, Rhodes J, Green JT, Hawkes ND, Swift JL, Srivastava ED, Evans BK, Williams GT, Newcombe RG, Courtney E, Pillai S. A randomized trial of nicotine enemas for active ulcerative colitis. Clin Gastroenterol Hepatol. 2005 Nov;3(11):1107-14. 

Durai D, Hawthorne AB. Review article: how and when to use ciclosporin in ulcerative colitis. Aliment Pharmacol Ther. 2005 Nov 15;22(10):907-16. 

Teml A, Schwab M, Harrer M, Miehsler W, Schaeffeler E, Dejaco C, Mantl M, Schneider B, Vogelsang H, Reinisch W. A prospective, open-label trial of 6-thioguanine in patients with ulcerative or indeterminate colitis. Scand J Gastroenterol. 2005 Oct;40(10):1205-13. 

Isaacs KL, Lewis JD, Sandborn WJ, Sands BE, Targan SR. State of the art: IBD therapy and clinical trials in IBD. Inflamm Bowel Dis. 2005 Nov;11 Suppl 1:S3-12. Review.  

Matula S, Croog V, Itzkowitz S, Harpaz N, Bodian C, Hossain S, Ullman T. Chemoprevention of colorectal neoplasia in ulcerative colitis: the effect of 6-mercaptopurine. Clin Gastroenterol Hepatol. 2005 Oct;3(10):1015-21.  

Suzuki A, Mitsuyama K, Koga H, Tomiyasu N, Masuda J, Takaki K, Tsuruta O, Toyonaga A, Sata M. Bifidogenic growth stimulator for the treatment of active ulcerative colitis: a pilot study.
Nutrition. 2005 Oct 10;  

Haskell H, Andrews CW Jr, Reddy SI, Dendrinos K, Farraye FA, Stucchi AF, Becker JM, Odze RD. Pathologic features and clinical significance of "backwash" ileitis in ulcerative colitis. Am J Surg Pathol. 2005 Nov;29(11):1472-81. 

Beniada A, Benoist G, Maurel J, Dreyfus M.  [Inflammatory bowel disease and pregnancy: report of 76 cases and review of the literature] J Gynecol Obstet Biol Reprod (Paris). 2005 Oct;34(6):581-8. Review. 

Miyata M, Kasugai K, Ishikawa T, Kakumu S, Onishi M, Mori T. Rebamipide enemas-new effective treatment for patients with corticosteroid dependent or resistant ulcerative colitis.
Dig Dis Sci. 2005 Oct;50 Suppl 1:S119-23.  

Auslander JN, Lieberman DA, Sonnenberg A. Lack of seasonal variation in the endoscopic diagnoses of Crohn's disease and ulcerative colitis. Am J Gastroenterol. 2005 Oct;100(10):2233-8.  

Abdelrazeq AS, Wilson TR, Leitch DL, Lund JN, Leveson SH. Ileitis in ulcerative colitis: is it a backwash? Dis Colon Rectum. 2005 Nov;48(11):2038-46. 

Ingram JR, Rhodes J, Collins PW, Williams GT, Newcombe RG, Thomas GA. Plasma fibrinogen in ulcerative colitis: the effect of disease activity and nicotine therapy in a randomised controlled trial. Dig Liver Dis. 2005 Nov;37(11):832-7.   

van Staa TP, Card T, Logan RF, Leufkens HG. 5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study. Gut. 2005 Nov;54(11):1573-8. Epub 2005 Jun 30. Review. 

Janke KH, Steder-Neukamm U, Bauer M, Raible A, Meisner C, Hoffmann JC, Gregor M, Klump B, Hauser W. Quality of Life Assessment in Inflammatory Bowel Disease (IBD): German Version of the Inflammatory Bowel Disease Questionnaire (IBDQ-D; Disease-Specific Instrument for Quality of Life Assessment) - First Application and Comparison with International Investigations. Gesundheitswesen. 2005 Aug-Sep;67(8-9):656-64. German.

Lindberg J, Stenling R, Palmqvist R, Rutegard J. Efficiency of colorectal cancer surveillance in patients with ulcerative colitis: 26 years' experience in a patient cohort from a defined population area. Scand J Gastroenterol. 2005 Sep;40(9):1076-80.

Tsujikawa T, Andoh A, Sakaki M, Ishizuka I, Araki Y, Koyama S, Fujiyama Y. Operative indications for patients with refractory or severe ulcerative colitis.
Hepatogastroenterology. 2005 Sep-Oct;52(65):1470-3. 

Stange EF, Schmid M, Fellermann K, Wehkamp J.  [Chronic inflammatory bowel diseases (IBD): novel pathophysiological concepts and their clinical relevance] Schweiz Rundsch Med Prax. 2005 Sep 14;94(37):1429-32.

Karimi O, Pena AS, van Bodegraven AA. Probiotics (VSL#3) in arthralgia in patients with ulcerative colitis and Crohn's disease: A pilot study. Drugs Today (Barc). 2005 Jul;41(7):453-9.
 

Abdelrazeq AS, Wilson TR, Leitch DL, Lund JN, Leveson SH. Ileitis in Ulcerative Colitis: Is It a Backwash? Dis Colon Rectum. 2005 Aug 29;

Torok HP, Glas J, Hollay HC, Gruber R, Osthoff M, Tonenchi L, Bruckl C, Mussack T, Folwaczny M, Folwaczny C. Serum Antibodies in First-Degree Relatives of Patients with IBD: A Marker of Disease Susceptibility? A Follow-Up Pilot-Study after 7 Years.
Digestion. 2005 Sep 16;72(2-3):119-123

Ingram JR, Rhodes J, Collins PW, Williams GT, Newcombe RG, Thomas GA. Plasma fibrinogen in ulcerative colitis: The effect of disease activity and nicotine therapy in a randomised controlled trial.
Dig Liver Dis. 2005 Sep 14;  

Silverberg MS, Satsangi J, Ahmad T, Arnott ID, Bernstein CN, Brant SR, Caprilli R, Colombel JF, Gasche C, Geboes K, Jewell DP, Karban A, Loftus Jr EV, Pena AS, Riddell RH, Sachar DB, Schreiber S, Steinhart AH, Targan SR, Vermeire S, Warren BF.  Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology.
Can J Gastroenterol. 2005 Sep;19 Suppl A:5-36.

Ingram JR, Rhodes J, Evans BK, Newcombe RG, Thomas GA. Comparative study of enema retention and preference in ulcerative colitis. Postgrad Med J. 2005 Sep;81(959):594-8.

Bernstein CN, Wajda A, Blanchard JF. The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population-based study. Gastroenterology. 2005 Sep;129(3):827-36.

Marohn MR, Hanly EJ, McKenna KJ, Varin CR. Laparoscopic Total Abdominal Colectomy in the Acute Setting. J Gastrointest Surg. 2005 September - October;9(7):881-887.

Larson DW, Dozois E, Sandborn WJ, Cima R. Total laparoscopic proctocolectomy with Brooke ileostomy: a novel incisionless surgical treatment for patients with ulcerative colitis. Surg Endosc. 2005 Jul 28;

Brunner M, Vogelsang H, Greinwald R, Kletter K, Kvaternik H, Schrolnberger C, Eichler HG, Brunner H, Dudczak R, Muller M. Colonic spread and serum pharmacokinetics of budesonide foam in patients with mildly to moderately active ulcerative colitis.
Aliment Pharmacol Ther. 2005 Sep 1;22(5):463-70.

Park IJ, Yu CS, Kim HC, Jung YH, Han KR, Yang SK, Kim JC. Analysis of pouchitis after restorative proctocolectomy Korean J Gastroenterol. 2005 Aug;46(2):99-104.

Trickett JP, Tilney HS, Gudgeon AM, Mellor SG, Edwards DP. Management of the rectal stump after emergency sub-total colectomy: which surgical option is associated with the lowest morbidity?
Colorectal Dis. 2005 Sep;7(5):519-22.

Israeli E, Grotto I, Gilburd B, Balicer RD, Goldin E, Wiik A, Shoenfeld Y. Anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies as predictors of inflammatory bowel disease. Gut. 2005 Sep;54(9):1232-6.

Matsushita M, Takakuwa H, Matsubayashi Y, Nishio A, Ikehara S, Okazaki K. Appendix is a priming site in the development of ulcerative colitis.
World J Gastroenterol. 2005 Aug 21;11(31):4869-74.

Mitomi H, Okayasu I, Bronner MP, Kanazawa H, Nishiyama Y, Otani Y, Sada M, Tanabe S, Igarashi M, Katsumata T, Saigenji K.  Comparative histologic assessment of proctocolectomy specimens from Japanese and American patients with ulcerative colitis with or without dysplasia. Int J Surg Pathol. 2005 Jul;13(3):259-65.

Ockenga J, Borchert K, Stuber E, Lochs H, Manns MP, Bischoff SC. Glutamine-enriched total parenteral nutrition in patients with inflammatory bowel disease.
Eur J Clin Nutr. 2005 Aug 3;

van der Woude CJ, Moshage H, Homan M, Kleibeuker JH, Jansen PL, van Dekken H.Expression of apoptosis related proteins during malignant progression in chronic ulcerative colitis.
J Clin Pathol. 2005 Aug;58(8):811-4.

Targan SR, Karp LC. Defects in mucosal immunity leading to ulcerative colitis. Immunol Rev. 2005 Aug;206:296-305.

Solem CA, Loftus EV Jr, Tremaine WJ, Harmsen WS, Zinsmeister AR, Sandborn WJ. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease.Inflamm Bowel Dis. 2005 Aug;11(8):707-12.

Zhong YQ, Huang HR, Zhu ZH, Chen QK, Zhan J, Xing LC. Effects of sulfasalazine on biopsy mucosal pathologies and histological grading of patients with active ulcerative colitis. World J Gastroenterol. 2005 Jul 28;11(28):4435-8.

Chambers WM, Warren BF, Jewell DP, Mortensen NJ. Cancer surveillance in ulcerative colitis.
Br J Surg. 2005 Aug;92(8):928-36. Review.

Bednarz W, Olewinski R, Wojczys R, Sutkowski K, Domoslawski P, Balcerzak W. Ileal-pouch-anal anastomosis after restorative proctocolectomy in patients with ulcerative colitis or familial adenomatous polyposis.Hepatogastroenterology. 2005 Jul-Aug;52(64):1101-5.

Gosselink MP, West RL, Kuipers EJ, Hansen BE, Schouten WR. Integrity of the anal sphincters after pouch-anal anastomosis: evaluation with three-dimensional endoanal ultrasonography. Dis Colon Rectum. 2005 Sep;48(9):1728-35.

Arai K, Koganei K, Kimura H, Akatani M, Kitoh F, Sugita A, Fukushima T. Incidence and outcome of complications following restorative proctocolectomy.
Am J Surg. 2005 Jul;190(1):39-42.

Marteau P, Probert CS, Lindgren S, Gassul M, Tan TG, Dignass A, Befrits R, Midhagen G, Rademaker J, Foldager M. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study.
Gut. 2005 Jul;54(7):960-5.

Gibson PR, Muir JG. Reinforcing the mucus: a new therapeutic approach for ulcerative colitis? Gut. 2005 Jul;54(7):900-3. Review.

Gionchetti P, Lammers KM, Rizzello F, Campieri M. Probiotics and barrier function in colitis. Gut. 2005 Jul;54(7):898-900. Review.

Abdelrazeq AS, Lund JN, Leveson SH. Implications of pouchitis on the functional results following stapled restorative proctocolectomy. Dis Colon Rectum. 2005 Sep;48(9):1700-7.

Ikeuchi H, Nakano H, Uchino M, Nakamura M, Noda M, Yanagi H, Yamamura T. Safety of one-stage restorative proctocolectomy for ulcerative colitis.
Dis Colon Rectum. 2005 Aug;48(8):1550-5.

van Staa TP, Card TR, Leufkens HG, Logan RF. 5-aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study. Gut. 2005 Jun 30;

Johnson GJ, Cosnes J, Mansfield JC. Review article: smoking cessation as primary therapy to modify the course of Crohn's disease. Aliment Pharmacol

Silberer H, Kuppers B, Mickisch O, Baniewicz W, Drescher M, Traber L, Kempf A, Schmidt-Gayk H. Fecal leukocyte proteins in inflammatory bowel disease and irritable bowel syndrome. Clin Lab. 2005;51(3-4):117-26.  

Sood A, Midha V, Sood N, Avasthi G. Azathioprine versus sulfasalazine in maintenance of remission in severe ulcerative colitis. Indian J Gastroenterol. 2003 May-Jun;22(3):79-81.

Candelli M, Papa A, Nista EC, Danese S, Armuzzi A, Bartolozzi F, Tondi P, Ojetti V, Gasbarrini G, Gasbarrini A. Antibodies to Saccharomyces cerevisiae: are they useful in clinical practice? Hepatogastroenterology. 2003 May-Jun;50(51):718-20.

Vind I, Johansen JS, Price PA, Munkholm P. Serum YKL-40, a potential new marker of disease activity in patients with inflammatory bowel disease Scand J Gastroenterol. 2003 Jun;38(6):599-605.

Tanaka M, Kusumi T, Oshitani N, Nishigami T, Iwao Y, Hatada Y, Sugita A, Yao T, Takano M, Iizuka B, Mukai M, Maeda K, Fukuda S, Morita T, Hara M, Saito H, Kudo H. Validity of simple mucosal biopsy criteria combined with endoscopy predicting patients with ulcerative colitis ultimately requiring surgery: a multicenter study Scand J Gastroenterol. 2003 Jun;38(6):594-8.

Campieri M, Adamo S, Valpiani D, D'Arienzo A, D'Albasio G, Pitzalis M, Cesari P, Casetti T, Castiglione GN, Rizzello F, Manguso F, Varoli G, Gionchetti P. Oral beclometasone dipropionate in the treatment of extensive and left-sided active ulcerative colitis: a multicentre randomised study. Aliment Pharmacol Ther. 2003 Jun 15;17(12):1471-80.

Kane SV, Sandborn WJ, Rufo PA, Zholudev A, Boone J, Lyerly D, Camilleri M, Hanauer SB. Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation.
Am J Gastroenterol. 2003 Jun;98(6):1309-14.  

Halfvarson J, Bodin L, Tysk C, Lindberg E, Jarnerot G. Inflammatory bowel disease in a Swedish twin cohort: a long-term follow-up of concordance and clinical characteristics. Gastroenterology. 2003 Jun;124(7):1767-73.  

Hilsden RJ, Verhoef MJ, Best A, Pocobelli G. A national survey on the patterns of treatment of inflammatory bowel disease in Canada. BMC Gastroenterol. 2003 Jun 5;3(1):10. Epub 2003 Jun 05

Sandborn WJ, Sands BE, Wolf DC, Valentine JF, Safdi M, Katz S, Isaacs KL, Wruble LD, Katz J, Present DH, Loftus EV Jr, Graeme-Cook F, Odenheimer DJ, Hanauer SB. Repifermin (keratinocyte growth factor-2) for the treatment of active ulcerative colitis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Aliment Pharmacol Ther. 2003 Jun 1;17(11):1355-64.  

Oshitani N, Kamata N, Ooiso R, Kawashima D, Inagawa M, Sogawa M, Iimuro M, Jinno Y, Watanabe K, Higuchi K, Matsumoto T, Arakawa T. Outpatient treatment of moderately severe active ulcerative colitis with pulsed steroid therapy and conventional steroid therapy. Dig Dis Sci. 2003 May;48(5):1002-5.  

Bruewer M, Krieglstein CF, Utech M, Bode M, Rijcken E, Anthoni C, Laukoetter MG, Schuermann G, Senninger N. Is Colonoscopy Alone Sufficient to Screen for Ulcerative Colitis-associated Colorectal Carcinoma? World J Surg. 2003 May;27(5):611-5. Epub 2003 Apr 28.

Fogt F. Sporadic adenomas in chronic ulcerative colitis. Z Gastroenterol. 2003 Apr;41(4):343-6.

Kiesslich R, Fritsch J, Holtmann M, Koehler HH, Stolte M, Kanzler S, Nafe B, Jung M, Galle PR, Neurath MF. Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis. Gastroenterology. 2003 Apr;124(4):880-8.

Jowett SL, Seal CJ, Phillips E, Gregory W, Barton JR, Welfare MR.  Defining relapse of ulcerative colitis using a symptom-based activity index. Scand J Gastroenterol. 2003 Feb;38(2):164-71.

Lam EC, Bailey RJ.  Infliximab salvage therapy after cyclosporine in an acute flare of chronic ulcerative colitis.
Can J Gastroenterol. 2003 Mar;17(3):198-200.

Saito S, Tsuno NH, Sunami E, Hori N, Kitayama J, Kazama S, Okaji Y, Kawai K, Kanazawa T, Watanabe T, Shibata Y, Nagawa H. Expression of platelet-derived endothelial cell growth factor in inflammatory bowel disease. J Gastroenterol. 2003;38(3):229-37.

Schroder O, Stein J. Low dose methotrexate in inflammatory bowel disease: current status and future directions.
Am J Gastroenterol. 2003 Mar;98(3):530-7. Review.

Rai S, Hemingway D. Acute adrenal insufficiency presenting as high output ileostomy.
Ann R Coll Surg Engl. 2003 Mar;85(2):105-6.

Jo Y, Matsumoto T, Yada S, Nakamura S, Yao T, Hotokezaka M, Mibu R, Iida M. Histological and immunological features of appendix in patients with ulcerative colitis. Dig Dis Sci. 2003 Jan;48(1):99-108.

Vernia P, Annese V, Bresci G, d'Albasio G, D'Inca R, Giaccari S, Ingrosso M, Mansi C, Riegler G, Valpiani D, Caprilli R. Topical butyrate improves efficacy of 5-ASA in refractory distal ulcerative colitis: results of a multicentre trial. Eur J Clin Invest. 2003 Mar;33(3):244-8.

Kanauchi O, Serizawa I, Araki Y, Suzuki A, Andoh A, Fujiyama Y, Mitsuyama K, Takaki K, Toyonaga A, Sata M, Bamba T. Germinated barley foodstuff, a prebiotic product, ameliorates inflammation of colitis through modulation of the enteric environment. J Gastroenterol. 2003;38(2):134-41.

Hisabe T, Matsui T, Sakurai T, Murakami Y, Tanabe H, Matake H, Yao T, Kamachi S, Iwashita A.  Anti- Saccharomyces cerevisiae antibodies in Japanese patients with inflammatory bowel disease: diagnostic accuracy and clinical value. J Gastroenterol. 2003;38(2):121-6.

Babic Z, Jagic V, Petrovic Z, Bilic A, Dinko K, Kubat G, Troskot R, Vukelic M. Elevated serum values of procollagen III peptide (PIIIP) in patients with ulcerative colitis who will develop pseudopolyps. World J Gastroenterol. 2003 Mar;9(3):619-21.

Okamura S, Aoki H, Ohashi S, Urano F, Shimodaira M, Kanamori S, Ishikawa H, Segawa K.  Efficacy of cyclosporin with corticotropin for refractory ulcerative colitis. Hepatogastroenterology. 2003 Jan-Feb;50(49):91-4.

Seidelin JB, Nielsen OH.  [Apoptosis in chronic inflammatory bowel disease. The importance for pathogenesis and treatment] Ugeskr Laeger. 2003 Feb 17;165(8):790-2. Danish.

Folwaczny C.  [Coagulation system and inflammatory bowel disease: therapeutic and pathophysiologic implications] Z Gastroenterol. 2002 Dec;40(12):991-8. Review. German.

Fraser AG. Methotrexate: first-line or second-line immunomodulator? Eur J Gastroenterol Hepatol. 2003 Mar;15(3):225-31.

McGovern DP, Travis SP. Thiopurine therapy: when to start and when to stop. Eur J Gastroenterol Hepatol. 2003 Mar;15(3):219-23.

Collins SM, McHugh K, Croitoru K, Howorth M. The establishment of a national tissue bank for inflammatory bowel disease research in Canada. Can J Gastroenterol. 2003 Feb;17(2):107-9.

Vilalta Castel E, Alcazar Montero MS, Navarro Gaspar C, Gimeno Aranguez M. Role of Clostridium difficile infection in the relapse of ulcerative colitis] An Med Interna. 2002 Dec;19(12):637-9. Spanish.

Van Assche G, Dalle I, Noman M, Aerden I, Swijsen C, Asnong K, Maes B, Ceuppens J, Geboes K, Rutgeerts P. A pilot study on the use of the humanized anti-interleukin-2 receptor antibody daclizumab in active ulcerative colitis. Am J Gastroenterol. 2003 Feb;98(2):369-76.

Nohara H, Saito Y, Higaki S, Okayama N, Hamanaka Y, Okita K, Hinoda Y.  Polymorphisms of the IL-1beta and IL-1beta-inducible genes in ulcerative colitis. J Gastroenterol. 2002 Nov;37 Suppl 14:107-10.

Mitsuyama K, Toyonaga A, Sata M. Intestinal microflora as a therapeutic target in inflammatory bowel disease. J Gastroenterol. 2002 Nov;37 Suppl 14:73-7. Review.

Kanauchi O, Suga T, Tochihara M, Hibi T, Naganuma M, Homma T, Asakura H, Nakano H, Takahama K, Fujiyama Y, Andoh A, Shimoyama T, Hida N, Haruma K, Koga H, Mitsuyama K, Sata M, Fukuda M, Kojima A, Bamba T. Treatment of ulcerative colitis by feeding with germinated barley foodstuff: first report of a multicenter open control trial. J Gastroenterol. 2002 Nov;37 Suppl 14:67-72.

Ishikawa H, Akedo I, Umesaki Y, Tanaka R, Imaoka A, Otani T. Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis. J Am Coll Nutr. 2003 Feb;22(1):56-63.

Andus T, Klebl F, Rogler G, Bregenzer N, Scholmerich J, Straub RH. Patients with refractory Crohn's disease or ulcerative colitis respond to dehydroepiandrosterone: a pilot study. Aliment Pharmacol Ther. 2003 Feb;17(3):409-14.

McKenna BJ, Appelman HD. Dysplasia can be a pain in the gut. Pathology. 2002 Dec;34(6):518-28.

Nielsen SE, Nielsen OH, Vainer B, Claesson MH. [Inflammatory bowel disease--do microorganisms play a role?] Ugeskr Laeger. 2002 Dec 9;164(50):5947-50. Review. Danish.

Ludwiczek O, Kaser A, Tilg H. Plasma levels of soluble CD40 ligand are elevated in inflammatory bowel diseases. Int J Colorectal Dis. 2003 Mar;18(2):142-7.

Paoluzi P, D'Albasio G, Pera A, Bianchi Porro G, Paoluzi OA, Pica R, Cottone M, Miglioli M, Prantera C, Sturniolo G, Ardizzone S. Oral and topical 5-aminosalicylic acid (mesalazine) in inducing and maintaining remission in mild-moderate relapse of ulcerative colitis: one-year randomised multicentre trial. Dig Liver Dis. 2002 Nov;34(11):787-93.

Carvalho AT, Elia CC, De Souza HS, Elias PR, Pontes EL, Lukashok HP, De Freitas FC, Lapa E Silva JR. Immunohistochemical study of intestinal eosinophils in inflammatory bowel disease. J Clin Gastroenterol. 2003 Feb;36(2):120-5.

Hart AL, Stagg AJ, Kamm MA. Use of probiotics in the treatment of inflammatory bowel disease. J Clin Gastroenterol. 2003 Feb;36(2):111-9.

Kane S, Huo D, Aikens J, Hanauer S. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med. 2003 Jan;114(1):39-43.

Abraham N, Selby W, Lazarus R, Solomon M. Is smoking an indirect risk factor for the development of ulcerative colitis? An age- and sex-matched case-control study. J Gastroenterol Hepatol. 2003 Feb;18(2):139-46.

Norgard B, Fonager K, Pedersen L, Jacobsen BA, Sorensen HT. Birth outcome in women exposed to 5-aminosalicylic acid during pregnancy: a Danish cohort study. Gut. 2003 Feb;52(2):243-7.

Richardson CE, Morgan JM, Jasani B, Green JT, Rhodes J, Williams GT, Lindstrom J, Wonnacott S, Peel S, Thomas GA. Effect of smoking and transdermal nicotine on colonic nicotinic acetylcholine receptors in ulcerative colitis. QJM. 2003 Jan;96(1):57-65.

Galandi D, Allgaier HP. [Diet therapy in chronic inflammatory bowel disease: results from meta-analysis and randomized controlled trials] Schweiz Rundsch Med Prax. 2002 Nov 20;91(47):2041-9. Review. German.

Pruitt R, Hanson J, Safdi M, Wruble L, Hardi R, Johanson J, Koval G, Riff D, Winston B, Cross A, Doty P, Johnson LK. Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis. Am J Gastroenterol. 2002 Dec;97(12):3078-86.

Piodi LP, Bardella M, Rocchia C, Cesana BM, Baldassarri A, Quatrini M.  Possible protective effect of 5-aminosalicylic acid on Helicobacter pylori infection in patients with inflammatory bowel disease. J Clin Gastroenterol. 2003 Jan;36(1):22-5. 

Simopoulos AP. Omega-3 Fatty acids in inflammation and autoimmune diseases.
J Am Coll Nutr. 2002 Dec;21(6):495-505.

Jensen MB, Houborg KB, Vestergaard P, Kissmeyer-Nielsen P, Mosekilde L, Laurberg S. Improved physical performance and increased lean tissue and fat mass in patients with ulcerative colitis four to six years after ileoanal anastomosis with a J-pouch. Dis Colon Rectum. 2002 Dec;45(12):1601-7.

Montgomery SM, Lambe M, Wakefield AJ, Pounder RE, Ekbom A. Siblings and the risk of inflammatory bowel disease. Scand J Gastroenterol. 2002 Nov;37(11):1301-8.

Bentley E, Jenkins D, Campbell F, Warren B. How could pathologists improve the initial diagnosis of colitis? Evidence from an international workshop. J Clin Pathol. 2002 Dec;55(12):955-60. Review.

Shand A, Forbes A. Potential therapeutic role for cytokine or adhesion molecule manipulation in Crohn's disease: in the shadow of infliximab? Int J Colorectal Dis. 2003 Jan;18(1):1-11.

Eaden J, Abrams K, Shears J, Mayberry J. Randomized controlled trial comparing the efficacy of a video and information leaflet versus information leaflet alone on patient knowledge about surveillance and cancer risk in ulcerative colitis. Inflamm Bowel Dis. 2002 Nov;8(6):407-12.

McLaren WJ, Anikijenko P, Thomas SG, Delaney PM, King RG. In vivo detection of morphological and microvascular changes of the colon in association with colitis using fiberoptic confocal imaging (FOCI). Dig Dis Sci. 2002 Nov;47(11):2424-33.

Konig HH, Ulshofer A, Gregor M, von Tirpitz C, Reinshagen M, Adler G, Leidl R. Validation of the EuroQol questionnaire in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2002 Nov;14(11):1205-15.

Garcia-Planella E, Domenech E, Cabre E, Bernal MI, Gassull MA.  [Intravenous cyclosporine A in the treatment of refractory Crohn's disease] Med Clin (Barc). 2002 Nov 9;119(16):610-2. Spanish.

Lamb EJ, Wong T, Smith DJ, Simpson DE, Coakley AJ, Moniz C, Muller AF. Metabolic bone disease is present at diagnosis in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2002 Nov;16(11):1895-902.

Rubin G, Hungin AP, Chinn D, Dwarakanath AD, Green L, Bates J. Long-term aminosalicylate therapy is under-used in patients with ulcerative colitis: a cross-sectional survey. Aliment Pharmacol Ther. 2002 Nov;16(11):1889-93.

Bernstein CN, Eaden J, Steinhart AH, Munkholm P, Gordon PH. Cancer prevention in inflammatory bowel disease and the chemoprophylactic potential of 5-aminosalicylic acid.
Inflamm Bowel Dis. 2002 Sep;8(5):356-61.

Bernklev T, Moum B, Moum T. Quality of life in patients with inflammatory bowel disease: translation, data quality, scaling assumptions, validity, reliability and sensitivity to change of the Norwegian version of IBDQ.
Scand J Gastroenterol. 2002 Oct;37(10):1164-74.

Actis GC, Bruno M, Pinna-Pintor M, Rossini FP, Rizzetto M. Infliximab for treatment of steroid-refractory ulcerative colitis. Dig Liver Dis. 2002 Sep;34(9):631-4. PMID: 12405249 [PubMed - in process]

Kohn A, Prantera C, Pera A, Cosintino R, Sostegni R, Daperno M. Anti-tumour necrosis factor alpha (infliximab) in the treatment of severe ulcerative colitis: result of an open study on 13 patients.
Dig Liver Dis. 2002 Sep;34(9):626-30.

Su C, Salzberg BA, Lewis JD, Deren JJ, Kornbluth A, Katzka DA, Stein RB, Adler DR, Lichtenstein GR. Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis. Am J Gastroenterol. 2002 Oct;97(10):2577-84.

Heinzlmann M, Lang SM, Neynaber S, Reinshagen M, Emmrich J, Stratakis DF, Heldwein W, Wiebecke B, Loeschke K. Screening for p53 and K-ras mutations in whole-gut lavage in chronic inflammatory bowel disease.
Eur J Gastroenterol Hepatol. 2002 Oct;14(10):1061-6. PMID: 12362095 [PubMed - in process]

Malcomson RD, McGregor AH. Molecular screening for colon cancer in inflammatory bowel disease.
Eur J Gastroenterol Hepatol. 2002 Oct;14(10):1045-7.

Sood A, Midha V, Sood N, Awasthi G. A prospective, open-label trial assessing dexamethasone pulse therapy in moderate to severe ulcerative colitis. J Clin Gastroenterol. 2002 Oct;35(4):328-31.

McCormack G, McCormick PA, Hyland JM, O'Donoghue DP. Cyclosporin therapy in severe ulcerative colitis: is it worth the effort?
Dis Colon Rectum. 2002 Sep;45(9):1200-5. PMID: 12352237 [PubMed - indexed for MEDLINE]

Linskens RK, Mallant-Hent RC, Groothuismink ZM, Bakker-Jonges LE, van de Merwe JP, Hooijkaas H, von Blomberg BM, Meuwissen SG. Evaluation of serological markers to differentiate between ulcerative colitis and Crohn's disease: pANCA, ASCA and agglutinating antibodies to anaerobic coccoid rods.

Paoluzi OA, Pica R, Marcheggiano A, Crispino P, Iacopini F, Iannoni C, Rivera M, Paoluzi P. Azathioprine or methotrexate in the treatment of patients with steroid-dependent or steroid-resistant ulcerative colitis: results of an open-label study on efficacy and tolerability in inducing and maintaining remission.
Aliment Pharmacol Ther. 2002 Oct;16(10):1751-9.

Ransford RA, Langman MJ. Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines.
Gut. 2002 Oct;51(4):536-9

Kobayashi T, Okamura S, Ohashi S, Urano F, Kanamori S, Hosoi T, Kako K, Kurahashi M, Segawa K, Maeda M. [Is p53 immunohistochemistry useful for optimal decision for treatment of polypoid lesions in ulcerative colitis?]
Nippon Shokakibyo Gakkai Zasshi. 2002 Aug;99(8):917-24. Japanese.

Kim BG, Kim YS, Kim JS, Jung HC, Song IS. Diagnostic role of anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic antibodies in patients with inflammatory bowel disease.
Dis Colon Rectum. 2002 Aug;45(8):1062-9.

Musch E, Andus T, Malek M. Induction and maintenance of clinical remission by interferon-beta in patients with steroid-refractory active ulcerative colitis-an open long-term pilot trial. Aliment Pharmacol Ther. 2002 Jul;16(7):1233-9.

Fraser AG, Orchard TR, Robinson EM, Jewell DP. Long-term risk of malignancy after treatment of inflammatory bowel disease with azathioprine. Aliment Pharmacol Ther. 2002 Jul;16(7):1225-32.

Bresci G, Parisi G, Bertoni M, Capria A. Long-term maintenance treatment in ulcerative colitis: a 10-year follow-up. Dig Liver Dis. 2002 Jun;34(6):419-23.

Lindgren S, Lofberg R, Bergholm L, Hellblom M, Carling L, Ung KA, Schioler R, Unge P, Wallin C, Strom M, Persson T, Suhr OB. Effect of budesonide enema on remission and relapse rate in distal ulcerative colitis and proctitis. Scand J Gastroenterol. 2002 Jun;37(6):705-10.

Halme L, Turunen U, Helio T, Paavola P, Walle T, Miettinen A, Jarvinen H, Kontula K, Farkkila M. Familial and sporadic inflammatory bowel disease: comparison of clinical features and serological markers in a genetically homogeneous population. Scand J Gastroenterol. 2002 Jun;37(6):692-8.

Biasco G, Rossini FP, Hakim R, Brandi G, Di Battista M, Di Febo G, Calabrese C, Santucci R, Miglioli M. Cancer surveillance in ulcerative colitis: critical analysis of long-term prospective programme. Dig Liver Dis. 2002 May;34(5):339-42.

Levine DS, Riff DS, Pruitt R, Wruble L, Koval G, Sales D, Bell JK, Johnson LK. A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis. Am J Gastroenterol. 2002 Jun;97(6):1398-407.

Soetikno RM, Lin OS, Heidenreich PA, Young HS, Blackstone MO. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: A meta-analysis. Gastrointest Endosc. 2002 Jul;56(1):48-54.

Bentsen BS, Moum B, Ekbom A. Incidence of inflammatory bowel disease in children in southeastern Norway: a prospective population-based study 1990-94. Scand J Gastroenterol. 2002 May;37(5):540-5.

Middleton SJ, Naylor S, Woolner J, Hunter JO. A double-blind, randomized, placebo-controlled trial of essential fatty acid supplementation in the maintenance of remission of ulcerative colitis.
Aliment Pharmacol Ther. 2002 Jun;16(6):1131-

Gullberg K, Lindforss U, Zetterquist H, Stalberg D, Reinholt FP, Veress B, Tribukait B, Olivecrona H, Lofberg R. Cancer risk assessment in long-standing pouchitis. DNA aberrations are rare in transformed neoplastic pelvic pouch mucosa. Int J Colorectal Dis. 2002 Mar;17(2):92-7.

Rolny P, Sadik R. Longer term outcome of steroid refractory ulcerative colitis treated with intravenous cyclosporine without subsequent oral cyclosporine maintenance therapy. Int J Colorectal Dis. 2002 Mar;17(2):67-9.

Ullman TA, Loftus EV Jr, Kakar S, Burgart LJ, Sandborn WJ, Tremaine WJ. The fate of low grade dysplasia in ulcerative colitis. Am J Gastroenterol. 2002 Apr;97(4):922-7.

Mahadevan U, Loftus EV Jr, Tremaine WJ, Sandborn WJ. Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease. Am J Gastroenterol. 2002 Apr;97(4):910-4.

Rutgeerts P. A critical assessment of new therapies in inflammatory bowel disease. J Gastroenterol Hepatol. 2002 Feb;17 Suppl 1:176-185.

Nordin K, Pahlman L, Larsson K, Sundberg-Hjelm M, Loof L. Health-related quality of life and psychological distress in a population-based sample of Swedish patients with inflammatory bowel disease. Scand J Gastroenterol. 2002 Apr;37(4):450-7.

Ben-Arye E, Goldin E, Wengrower D, Stamper A, Kohn R, Berry E. Wheat grass juice in the treatment of active distal ulcerative colitis: a randomized double-blind placebo-controlled trial. Scand J Gastroenterol. 2002 Apr;37(4):444-9.

Conrad K, Schmechta H, Klafki A, Lobeck G, Uhlig HH, Gerdi S, Henker J. Serological differentiation of inflammatory bowel diseases. Eur J Gastroenterol Hepatol. 2002 Feb;14(2):129-35.

Lerner A, Shoenfeld Y. Serological markers in inflammatory bowel disease: the pros and cons. Eur J Gastroenterol Hepatol. 2002 Feb;14(2):103-5.

Bariol C, Meagher AP, Vickers CR, Byrnes DJ, Edwards PD, Hing M, Wettstein AR, Field A. Early studies on the safety and efficacy of thalidomide for symptomatic inflammatory bowel disease. J Gastroenterol Hepatol. 2002 Feb;17(2):135-9.

Okayasu I, Hana K, Yoshida T, Mikami T, Kanno J, Fujiwara M. Significant increase of colonic mutated crypts in ulcerative colitis correlatively with duration of illness. Cancer Res. 2002 Apr 15;62(8):2236-8.

van Bergeijk JD, Wilson JH, Nielsen OH, von Tirpitz C, Karvonen AL, Lygren I, Radler A, Waldum HL, Mulder CJ, Friis S, Tefera S, Hoogkamer JF. Octreotide in patients with active ulcerative colitis treated with high dose corticosteroids (OPUS 1). Eur J Gastroenterol Hepatol. 2002 Mar;14(3):243-8.

Polese L, Angriman I, Cecchetto A, Norberto L, Scarpa M, Ruffolo C, Barollo M, Sommariva A, D'Amico DF. The role of CD40 in ulcerative colitis: histochemical analysis and clinical correlation. Eur J Gastroenterol Hepatol. 2002 Mar;14(3):237-41.

Fraser AG, Morton D, McGovern D, Travis S, Jewell DP. The efficacy of methotrexate for maintaining remission in inflammatory bowel disease. Aliment Pharmacol Ther. 2002 Apr;16(4):693-7.

Howarth GF, Robinson MH, Jenkins D, Hardcastle JD, Logan RF. High prevalence of undetected ulcerative colitis: data from the Nottingham fecal occult blood screening trial. Am J Gastroenterol. 2002 Mar;97(3):690-4.

Mishkin D, Boston FM, Blank D, Yalovsky M, Mishkin S. The glucose breath test: a diagnostic test for small bowel stricture(s) in Crohn's disease. Dig Dis Sci. 2002 Mar;47(3):489-94.

Carlson M, Raab Y, Seveus L, Xu S, Hallgren R, Venge P. Human neutrophil lipocalin is a unique marker of neutrophil inflammation in ulcerative colitis and proctitis. Gut. 2002 Apr;50(4):501-6.

Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut. 2002 Apr;50(4):485-9.

Mukhtar H, Zak A, Berry AR. Restorative proctocolectomy: one surgeon's experience of a now routine procedure in a district general hospital. J R Coll Surg Edinb. 2002 Feb;47(1):400-6.

Higaki S, Nohara H, Saitoh Y, Akazawa A, Yanai H, Yoshida T, Okita K. Increased rectal wall thickness may predict relapse in ulcerative colitis: a pilot follow-up study by ultrasonographic colonoscopy.
Endoscopy. 2002 Mar;34(3):212-9.

Schimmelpenning H, Bruch HP. [J-pouch. Selection of patients and how to avoid malfunctions] Zentralbl Chir. 2001 Dec;126(Supplement I):32-5. German.

Coffey JC, Winter DC, Neary P, Murphy A, Redmond HP, Kirwan WO. Quality of life after ileal pouch-anal anastomosis: an evaluation of diet and other factors using the cleveland global quality of life instrument. Dis Colon Rectum. 2002 Jan;45(1):30-8.

Rintala RJ, Lindahl HG. Proctocolectomy and J-pouch ileo-anal anastomosis in children. J Pediatr Surg. 2002 Jan;37(1):66-70.

Madiba TE, Bartolo DC. Pouchitis following restorative proctocolectomy for ulcerative colitis: incidence and therapeutic outcome. J R Coll Surg Edinb. 2001 Dec;46(6):334-7.

Almogy G, Sachar DB, Bodian CA, Greenstein AJ. Surgery for ulcerative colitis in elderly persons: changes in indications for surgery and outcome over time. Arch Surg. 2001 Dec;136(12):1396-400.

Faucheron JL, Risse O, Letoublon C. A new ileal pouch salvage technique. Dis Colon Rectum. 2001 Dec;44(12):1891-4.

Takesue Y, Sakashita Y, Akagi S, Murakami Y, Ohge H, Imamura Y, Horikawa Y, Yokoyama T. Gut transit time after ileal pouch-anal anastomosis using a radiopaque marker. Dis Colon Rectum. 2001 Dec;44(12):1808-13.

Dunker MS, Bemelman WA, Slors JF, van Duijvendijk P, Gouma DJ. Functional outcome, quality of life, body image, and cosmesis in patients after laparoscopic-assisted and conventional restorative proctocolectomy: a comparative study. Dis Colon Rectum. 2001 Dec;44(12):1800-7.

Tulchinsky H, McCourtney JS, Rao KV, Chambers W, Williams J, Wilkinson KH, Nicholls RJ. Salvage abdominal surgery in patients with a retained rectal stump after restorative proctocolectomy and stapled anastomosis. Br J Surg. 2001 Dec;88(12):1602-6.

Heuschen UA, Hinz U, Allemeyer EH, Lucas M, Heuschen G, Herfarth C. One- or two-stage procedure for restorative proctocolectomy: rationale for a surgical strategy in ulcerative colitis. Ann Surg. 2001 Dec;234(6):788-94.

Kuisma J, Nuutinen H, Luukkonen P, Jarvinen H, Kahri A, Farkkila M. Long term metabolic consequences of ileal pouch-anal anastomosis for ulcerative colitis. Am J Gastroenterol. 2001 Nov;96(11):3110-6.

Achkar JP, Shen B. Medical management of postoperative complications of inflammatory bowel disease: pouchitis and Crohn's disease recurrence. Curr Gastroenterol Rep. 2001 Dec;3(6):484-90.

Joelsson M, Andersson M, Bark T, Gullberg K, Hallgren T, Jiborn H, Magnusson I, Raab Y, Sjodahl R, Ojerskog B, Oresland T. Allopurinol as prophylaxis against pouchitis following ileal pouch-anal anastomosis for ulcerative colitis. A randomized placebo-controlled double-blind study. Scand J Gastroenterol. 2001 Nov;36(11):1179-84.

Steens J, Bemelman WA, Meijerink WJ, Griffioen G, van Hogezand RA, Masclee AA. Ileoanal pouch function is related to postprandial pouch tone. Br J Surg. 2001 Nov;88(11):1492-7.

Fleshner PR, Vasiliauskas EA, Kam LY, Fleshner NE, Gaiennie J, Abreu-Martin MT, Targan SR. High level perinuclear antineutrophil cytoplasmic antibody (pANCA) in ulcerative colitis patients before colectomy predicts the development of chronic pouchitis after ileal pouch-anal anastomosis. Gut. 2001 Nov;49(5):671-7.

Holzmann K, Klump B, Borchard F, Gregor M, Porschen R. Flow cytometric and histologic evaluation in a large cohort of patients with ulcerative colitis: correlation with clinical characteristics and impact on surveillance. Dis Colon Rectum. 2001 Oct;44(10):1446-55.

Buchman AL, Fife C, Torres C, Smith L, Aristizibal J. Hyperbaric oxygen therapy for severe ulcerative colitis. J Clin Gastroenterol. 2001 Oct;33(4):337-9.

Robinson A, Thompson DG, Wilkin D, Roberts C. Guided self-management and patient-directed follow-up of ulcerative colitis: a randomised trial. Lancet. 2001 Sep 22;358(9286):976-81.

Campbell S, Ghosh S. Is neutropenia required for effective maintenance of remission during azathioprine therapy in inflammatory bowel disease? Eur J Gastroenterol Hepatol. 2001 Sep;13(9):1073-6.

Actis GC, Bresso F, Astegiano M, Demarchi B, Sapone N, Boscaglia C, Rizzetto M. Safety and efficacy of azathioprine in the maintenance of ciclosporin-induced remission of ulcerative colitis. Aliment Pharmacol Ther. 2001 Sep;15(9):1307-11.

Mantzaris GJ, Petraki K, Archavlis E, Amberiadis P, Kourtessas D, Christidou A, Triantafyllou G. A prospective randomized controlled trial of intravenous ciprofloxacin as an adjunct to corticosteroids in acute, severe ulcerative colitis. Scand J Gastroenterol. 2001 Sep;36(9):971-4.

Cucino C, Sonnenberg A. Cause of death in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2001 Aug;7(3):250-5.

Farup PG, Hinterleitner TA, Lukas M, Hebuterne X, Rachmilewitz D, Campieri M, Meier R, Keller R, Rathbone B, Oddsson E. Mesalazine 4 g daily given as prolonged-release granules twice daily and four times daily is at least as effective as prolonged-release tablets four times daily in patients with ulcerative colitis. Inflamm Bowel Dis. 2001 Aug;7(3):237-42.

Naganuma M, Iwao Y, Ogata H, Inoue N, Funakoshi S, Yamamoto S, Nakamura Y, Ishii H, Hibi T. Measurement of colonic mucosal concentrations of 5-aminosalicylic acid is useful for estimating its therapeutic efficacy in distal ulcerative colitis: comparison of orally administered mesalamine and sulfasalazine. Inflamm Bowel Dis. 2001 Aug;7(3):221-5.

Flood L, Lofberg R, Stierna P, Wikstrom AC. Glucocorticoid receptor mRNA in patients with ulcerative colitis: a study of responders and nonresponders to glucocorticosteroid therapy. Inflamm Bowel Dis. 2001 Aug;7(3):202-9.

Sandborn WJ, Loftus EV Jr, Colombel JF, Fleming KA, Seibold F, Homburger HA, Sendid B, Chapman RW, Tremaine WJ, Kaul DK, Wallace J, Harmsen WS, Zinsmeister AR, Targan SR. Evaluation of serologic disease markers in a population-based cohort of patients with ulcerative colitis and Crohn's disease. Inflamm Bowel Dis. 2001 Aug;7(3):192-201.

Chey WY, Hussain A, Ryan C, Potter GD, Shah A. Infliximab for refractory ulcerative colitis. Am J Gastroenterol. 2001 Aug;96(8):2373-81.

Odes HS, Fich A, Reif S, Halak A, Lavy A, Keter D, Eliakim R, Paz J, Broide E, Niv Y, Ron Y, Villa Y, Arber N, Gilat T. Effects of current cigarette smoking on clinical course of Crohn's disease and ulcerative colitis. Dig Dis Sci. 2001 Aug;46(8):1717-21.

Faubion WA Jr, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology. 2001 Aug;121(2):255-60.

Sands BE. Biological therapies for ulcerative colitis.
Acta Gastroenterol Belg. 2001 Apr-Jun;64(2):205-9. Review.

Sandborn WJ. Cyclosporine in ulcerative colitis: state of the art. Acta Gastroenterol Belg. 2001 Apr-Jun;64(2):201-4. Review.

Lapidus A. The changing epidemiology of inflammatory bowel diseases. Acta Gastroenterol Belg. 2001 Apr-Jun;64(2):155-9.

Bernstein CN, Kraut A, Blanchard JF, Rawsthorne P, Yu N, Walld R. The relationship between inflammatory bowel disease and socioeconomic variables. Am J Gastroenterol. 2001 Jul;96(7):2117-25.

Beaugerie L, Massot N, Carbonnel F, Cattan S, Gendre JP, Cosnes J. Impact of cessation of smoking on the course of ulcerative colitis. Am J Gastroenterol. 2001 Jul;96(7):2113-6.

Morris DL, Montgomery SM, Galloway ML, Pounder RE, Wakefield AJ. Inflammatory bowel disease and laterality: is left handedness a risk? Gut. 2001 Aug;49(2):199-202.

Ishaq S, Green JR. Tolerability of aminosalicylates in inflammatory bowel disease. BioDrugs. 2001;15(5):339-49. Review.
Bonapace ES, Srinivasan R. Simultaneous occurrence of inflammatory bowel disease and thyroid disease. Am J Gastroenterol. 2001 Jun;96(6):1925-6. Review.

Bru C, Sans M, Defelitto MM, Gilabert R, Fuster D, Llach J, Lomena F, Bordas JM, Pique JM, Panes J. Hydrocolonic sonography for evaluating inflammatory bowel disease. AJR Am J Roentgenol. 2001 Jul;177(1):99-105.

Eaden J, Abrams K, McKay H, Denley H, Mayberry J. Inter-observer variation between general and specialist gastrointestinal pathologists when grading dysplasia in ulcerative colitis.
J Pathol. 2001 Jun;194(2):152-7.

Uzan A, Jolly D, Berger E, Diebold MD, Geoffroy P, Renard P, Vandromme L, Bourgeois L, Ramaholimihaso F, Bouche O, Zeitoun P, Cadiot G, Thiefin G. [Protective effect of appendectomy on the development of ulcerative colitis. A case-control study]. Gastroenterol Clin Biol. 2001 Mar;25(3):239-42. French.

Chey WY. Infliximab for patients with refractory ulcerative colitis. Inflamm Bowel Dis. 2001 May;7 Suppl 1:S30-3.
Kho YH, Pool MO, Jansman FG, Harting JW. Pharmacotherapeutic options in inflammatory bowel disease: an update. Pharm World Sci. 2001 Feb;23(1):17-21. Review.

Rudolph MW, Klein S, Beckert TE, Petereit H, Dressman JB. A new 5-aminosalicylic acid multi-unit dosage form for the therapy of ulcerative colitis. Eur J Pharm Biopharm. 2001 May;51(3):183-90.

Michell NP, Lalor P, Langman MJ. Heparin therapy for ulcerative colitis? Effects and mechanisms. Eur J Gastroenterol Hepatol. 2001 Apr;13(4):449-56. Review.

Linskens RK, van Bodegraven AA, Schoorl M, Tuynman HA, Bartels P. Predictive value of inflammatory and coagulation parameters in the course of severe ulcerative colitis. Dig Dis Sci. 2001 Mar;46(3):644-8.

Bernstein CN, Blanchard JF, Rawsthorne P, Yu N. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol. 2001 Apr;96(4):1116-22.

Sangfelt P, Carlson M, Thorn M, Loof L, Raab Y. Neutrophil and eosinophil granule proteins as markers of response to local prednisolone treatment in distal ulcerative colitis and proctitis. Am J Gastroenterol. 2001 Apr;96(4):1085-90.

Askling J, Dickman PW, Karlen P, Brostrom O, Lapidus A, Lofberg R, Ekbom A. Family history as a risk factor for colorectal cancer in inflammatory bowel disease. Gastroenterology. 2001 May;120(6):1356-62.

D'Haens G, Lemmens L, Geboes K, Vandeputte L, Van Acker F, Mortelmans L, Peeters M, Vermeire S, Penninckx F, Nevens F, Hiele M, Rutgeerts P.  Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology. 2001 May;120(6):1323-9.

Sakata T, Niwa Y, Goto H, Hirooka Y, Hayakawa T, Ohmiya N, Kobayashi S. Asymptomatic inflammatory bowel disease with special reference to ulcerative colitis in apparently healthy persons. Am J Gastroenterol. 2001 Mar;96(3):735-9.

Nugent SG, Kumar D, Rampton DS, Evans DF. Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugs. Gut. 2001 Apr;48(4):571-7. Review.

Goudet P, Dozois RR, Kelly KA, Ilstrup DM, Phillips SF. Characteristics and evolution of extraintestinal manifestations associated with ulcerative colitis after proctocolectomy. Dig Surg. 2001;18(1):51-5.

Naganuma M, Iwao Y, Ogata H, Funakoshi S, Takagi H, Nakano M, Hitotsumatsu O, Ezaki T, Hisamatsu T, Inoue N, Hibi T, Ishii H. [Efficacy of mesalamine enema in the treatment of steroid-resistant or dependent distal ulcerative colitis]. Nippon Shokakibyo Gakkai Zasshi. 2001 Feb;98(2):151-6. Japanese.

Spinzi G, Belloni G, Martegani A, Sangiovanni A, Del Favero C, Minoli G. Computed tomographic colonography and conventional colonoscopy for colon diseases: a prospective, blinded study. Am J Gastroenterol. 2001 Feb;96(2):394-400.

Heuschen UA, Hinz U, Allemeyer EH, Stern J, Lucas M, Autschbach F, Herfarth C, Heuschen G. Backwash ileitis is strongly associated with colorectal carcinoma in ulcerative colitis. Gastroenterology. 2001 Mar;120(4):841-7.

Laharie D, Debeugny S, Peeters M, Van Gossum A, Gower-Rousseau C, Belaiche J, Fiasse R, Dupas JL, Lerebours E, Piotte S, Cortot A, Vermeire S, Grandbastien B, Colombel JF. Inflammatory bowel disease in spouses and their offspring. Gastroenterology. 2001 Mar;120(4):816-9.
Irvine EJ, Farrokhyar F, Swarbrick ET. A critical review of epidemiological studies in inflammatory bowel disease. Scand J Gastroenterol. 2001 Jan;36(1):2-15. Review.

Askling J, Dickman PW, Karlen P, Brostrom O, Lapidus A, Lofberg R, Ekbom A. Colorectal cancer rates among first-degree relatives of patients with inflammatory bowel disease: a population-based cohort study. Lancet. 2001 Jan 27;357(9252):262-6.

Aust DE, Terdiman JP, Willenbucher RF, Chew K, Ferrell L, Florendo C, Molinaro-Clark A, Baretton GB, Lohrs U, Waldman FM. Altered distribution of beta-catenin, and its binding proteins E-cadherin and APC, in ulcerative colitis-related colorectal cancers. Mod Pathol. 2001 Jan;14(1):29-39.

Bitton A, Peppercorn MA, Antonioli DA, Niles JL, Shah S, Bousvaros A, Ransil B, Wild G, Cohen A, Edwardes MD, Stevens AC. Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology. 2001 Jan;120(1):13-20.

Nos P, Hinojosa J, Gomollon F, Ponce J. [Budesonide in inflammatory bowel disease: a meta-analysis]. Med Clin (Barc). 2001 Jan 20;116(2):47-53. Review. Spanish.

Vecchi M, Meucci G, Gionchetti P, Beltrami M, Di Maurizio P, Beretta L, Ganio E, Usai P, Campieri M, Fornaciari G, de Franchis R. Oral versus combination mesalazine therapy in active ulcerative colitis: a double-blind, double-dummy, randomized multicentre study. Aliment Pharmacol Ther. 2001 Feb;15(2):251-6.

Hussain FN, Ajjan RA, Kapur K, Moustafa M, Riley SA. Once versus divided daily dosing with delayed-release mesalazine: a study of tissue drug concentrations and standard pharmacokinetic parameters. Aliment Pharmacol Ther. 2001 Jan;15(1):53-62.

Dig Liver Dis 2000 Aug-Sep;32(6):518-31

Azathioprine or 6-mercaptopurine for inflammatory bowel disease: do risks outweigh benefits? Su CG, Stein RB, Lewis JD, Lichtenstein GR

Dis Colon Rectum 2000 Oct;43(10 Suppl):S34-9 High proliferative activity is associated with dysplasia in ulcerative colitis. Shinozaki M, Watanabe T, Kubota Y, Sawada T, Nagawa H, Muto T

Dig Dis Sci 2000 Sep;45(9):1810-3 Use of 6-mercaptopurine in patients with inflammatory bowel disease previously intolerant of azathioprine. Bowen DG, Selby WS

Gastroenterology 2000 Oct;119(4):903-8 Comparison of heparin and steroids in the treatment of moderate and severe ulcerative colitis. Panes J, Esteve M, Cabre E, Hinojosa J, Andreu M, Sans M, Fernandez-Banares F, Feu F, Gassull MA, Pique JM

Eur J Clin Pharmacol 2000 Aug;56(5):353-62 The role of aminosalicylates at the beginning of the new millennium in thetreatment of chronic inflammatory bowel disease. Klotz U

Am J Gastroenterol 2000 Sep;95(9):2301-7 High frequencies of telomeric associations, chromosome aberrations, and sister chromatid exchanges in ulcerative colitis. Cottliar A, Fundia A, Boerr L, Sambuelli A, Negreira S, Gil A, Gomez JC, Chopita N, Bernedo A, Slavutsky I

Dig Dis Sci 2000 Aug;45(8):1594-600 Influence of disease site and activity on peripheral neutrophil function in inflammatory bowel disease. D'Odorico A, D'Inca R, Mestriner C, Di Leo V, Ferronato A, Sturniolo GC

Gastroenterology 2000 Sep;119(3):647-53 Hodgkin's disease risk is increased in patients with ulcerative colitis. Palli D, Trallori G, Bagnoli S, Saieva C, Tarantino O, Ceroti M, d'Albasio G, Pacini F, Amorosi A, Masala G

Isr Med Assoc J 2000 Aug;2(8):588-91 Cyclosporin for severe ulcerative colitis.Naftali T, Novis B, Pomeranz I, Leichtman G, Maor Y, Shapiro R, Moskowitz M, Avidan B, Avni Y, Bujanover Y, Fireman Z

Aliment Pharmacol Ther 2000 Sep;14(9):1191-8 Efficacy and tolerability of mesalazine foam enema (Salofalk foam) for distal ulcerative colitis: a double-blind, randomized, placebo-controlled study. Pokrotnieks J, Marlicz K, Paradowski L, Margus B, Zaborowski P, Greinwald R

Eur J Gastroenterol Hepatol 2000 Aug;12(8):899-905 Early changes of ileoanal pouch mucosa in patients with ulcerative colitis. Herbst F, Ciclitira PJ, Talbot IC, Nicholls RJ

Eur J Gastroenterol Hepatol 2000 Aug;12(8):855-62 Smoking and inflammatory bowel disease. Rubin DT, Hanauer SB

Cancer 2000 Aug 15;89(4):733-40 Decreased expression of CD44, alpha-catenin, and deleted colon carcinoma andaltered expression of beta-catenin in ulcerative colitis-associated dysplasiaand carcinoma, as compared with sporadic colon neoplasms. Mikami T, Mitomi H, Hara A, Yanagisawa N, Yoshida T, Tsuruta O, Okayasu I

Am J Gastroenterol 2000 Aug;95(8):2000-8 Factors predictive of response to cyclosporin treatment for severe, steroid-resistant ulcerative colitis. Rowe FA, Walker JH, Karp LC, Vasiliauskas EA, Plevy SE, Targan SR

Am J Gastroenterol 2000 Aug;95(8):1994-9 Higher expression of glucocorticoid receptor in peripheral mononuclear cells ininflammatory bowel disease. Schottelius A, Wedel S, Weltrich R, Rohde W, Buttgereit F, Schreiber S, Lochs H

Am J Gastroenterol 2000 Aug;95(8):1949-54 Effects of nonsteroidal antiinflammatory drugs on inflammatory bowel disease: acase-control study. Felder JB, Korelitz BI, Rajapakse R, Schwarz S, Horatagis AP, Gleim G

Am J Gastroenterol 2000 Aug;95(8):1946-8 Tolerance of nonsteroidal antiinflammatory drugs in patients with inflammatorybowel disease. Bonner GF, Walczak M, Kitchen L, Bayona M

Gut 2000 Sep;47(3):410-4 Mucosal 5-aminosalicylic acid concentration inversely correlates with severityof colonic inflammation in patients with ulcerative colitis.Frieri G, Giacomelli R, Pimpo M, Palumbo G, Passacantando A, Pantaleoni G, Caprilli R

Gut 2000 Sep;47(3):404-9 A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. Geboes K, Riddell R, Ost A, Jensfelt B, Persson T, Lofberg R

Chir Ital 2000 May-Jun;52(3):215-22 Immediate and long-term results in ileoanastomosis with reservoir in 335consecutive cases. [Article in Italian]Poggioli G, Laureti S, Stocchi L, Campieri M, Ugolini F, Salone M, Gionchetti P, Lauriola O, Rizzello F

Aliment Pharmacol Ther 2000 Aug;14(8):1015-22 Randomized comparison of unfractionated heparin with corticosteroids in severeactive inflammatory bowel disease.Ang YS, Mahmud N, White B, Byrne M, Kelly A, Lawler M, McDonald GS, Smith OP, Keeling PW

Gastroenterology 2000 Aug;119(2):305-9 Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gionchetti P, Rizzello F, Venturi A, Brigidi P, Matteuzzi D, Bazzocchi G, Poggioli G, Miglioli M, Campieri M

Am J Gastroenterol 2000 Jul;95(7):1749-54 Long-term use of mesalamine (Rowasa) suppositories in remission maintenance of ulcerative proctitis. Hanauer S, Good LI, Goodman MW, Pizinger RJ, Strum WB, Lyss C, Haber G, Williams CN, Robinson M

Am J Gastroenterol 2000 Jul;95(7):1628-36 Putting rectal 5-aminosalicylic acid in its place: the role in distal ulcerative colitis. Marshall JK, Irvine EJ

Eur J Gastroenterol Hepatol 2000 Jun;12(6):657-60 Audit of cyclosporin use in inflammatory bowel disease: limited benefits,numerous side-effects. Haslam N, Hearing SD, Probert CS

Cancer Res 2000 Jul 1;60(13):3333-7 Increased p53 mutation load in noncancerous colon tissue from ulcerativecolitis: a cancer-prone chronic inflammatory disease. Hussain SP, Amstad P, Raja K, Ambs S, Nagashima M, Bennett WP, Shields PG, Ham AJ, Swenberg JA, Marrogi AJ, Harris CC

Acta Med Austriaca 2000;27(3):91-3 Recurrent septicemia with lethal outcome during and after cyclosporine therapy in severe ulcerative colitis. Hinterreiter M, Stadler B, Knoflach P

Gastroenterology 2000 Jul;119(1):15-22 Surrogate markers of intestinal inflammation are predictive of relapse inpatients with inflammatory bowel disease. Tibble JA, Sigthorsson G, Bridger S, Fagerhol MK, Bjarnason I

Am Surg 2000 Jun;66(6):540-6; discussion 546-7 Ileoanal pouch versus ileostomy: is there a difference in quality of life? Seidel SA, Newman M, Sharp KW

J Submicrosc Cytol Pathol 2000 Jan;32(1):97-102 Effects of nicotine on intestinal epithelial cells in vivo and in vitro: anX-ray microanalytical study. Kozlova I, Dragomir A, Vanthanouvong V, Roomans GM

Hum Pathol 2000 Jun;31(6):665-71 Microsatellite instability and K-ras mutations in patients with ulcerativecolitis. Lyda MH, Noffsinger A, Belli J, Fenoglio-Preiser CM

World J Surg 2000 Jul;24(7):851-6 Risk factors and true incidence of pouchitis in patients after ileal pouch-anal anastomoses. Simchuk EJ, Thirlby RC

Inflamm Bowel Dis 2000 May;6(2):123-31 Prediction of treatment refractoriness in ulcerative colitis and Crohn's disease--do we have reliable markers? Gelbmann CM

Transfus Sci 2000 Jun;22(3):155-60 Preliminary experience with plasma exchange in patients with ulcerative colitis. Selset Aandahl G, Jacobsen CD, Rode L, Rathe Oedegaard E

Z Gastroenterol 2000 Apr;38(4):287-93 Budesonide foam as a new therapeutic principle in distal ulcerative colitis incomparison with mesalazine enema. An open, controlled, randomized and prospective multicenter pilot study. [Article in German] Rufle W, Fruhmorgen P, Huber W, Kimmig JM

Am J Gastroenterol 2000 May;95(5):1263-76 A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Cohen RD, Woseth DM, Thisted RA, Hanauer SB

Am J Gastroenterol 2000 May;95(5):1213-20 Stress and exacerbation in ulcerative colitis: a prospective study of patientsenrolled in remission. Levenstein S, Prantera C, Varvo V, Scribano ML, Andreoli A, Luzi C, Arca M,Berto E, Milite G, Marcheggiano A

Arch Surg 2000 May;135(5):582-5 Use of a microsatellite marker in predicting dysplasia in ulcerative colitis. Hunt LE, Eichenberger MR, Petras R, Galandiuk S

Drugs 2000 Apr;59(4):929-56 Prolonged-release mesalazine: a review of its therapeutic potential inulcerative colitis and Crohn's disease. Clemett D, Markham A

Cochrane Database Syst Rev 2000;(2):CD000544 Oral 5-aminosalicylic acid for maintaining remission in ulcerative colitis. Sutherland L, Roth D, Beck P, May G, Makiyama K

Cochrane Database Syst Rev 2000;(2):CD000543 Oral 5-aminosalicylic acid for inducing remission in ulcerative colitis. Sutherland L, Roth D, Beck P, May G, Makiyama K

Dig Dis Sci 2000 May;45(5):976-81 Combined oral sodium butyrate and mesalazine treatment compared to oralmesalazine alone in ulcerative colitis: randomized, double-blind,placebo-controlled pilot study. Vernia P, Monteleone G, Grandinetti G, Villotti G, Di Giulio E, Frieri G, Marcheggiano A, Pallone F, Caprilli R, Torsoli A

Rev Hosp Clin Fac Med Sao Paulo 1999 Sep-Oct;54(5):155-8 Pouchitis: extracolonic manifestation of ulcerative colitis? Teixeira WG, da Silva JH, Teixeira MG, Almeida M, Calache JE, Habr-Gama A

Gastroenterology 2000 May;118(5):859-66 Expression of glucocorticoid receptor beta in lymphocytes of patients withglucocorticoid-resistant ulcerative colitis. Honda M, Orii F, Ayabe T, Imai S, Ashida T, Obara T, Kohgo Y

Eur J Gastroenterol Hepatol 2000 Apr;12(4):439-43 Assessment of the prevalence of infection with Helicobacter pylori in patientswith inflammatory bowel disease. Pearce CB, Duncan HD, Timmis L, Green JR

Dig Dis Sci 2000 Mar;45(3):462-5 Age-related clinical severity at diagnosis in 1705 patients with ulcerativecolitis: a study by GISC (Italian Colon-Rectum Study Group). Riegler G, Tartaglione MT, Carratu R, D'Inca R, Valpiani D, Russo MI, Papi C, Fiorentini MT, Ingrosso M, Andreoli A, Vecchi M

Aliment Pharmacol Ther 2000 Mar;14(3):273-9 Predictive factors of outcome of intensive intravenous treatment for attacks ofulcerative colitis. Carbonnel F, Gargouri D, Lemann M, Beaugerie L, Cattan S, Cosnes J, Gendre JP

Ital J Gastroenterol Hepatol 1999 Nov;31(8):677-84 Mesalazine foam (Salofalk foam) in the treatment of active distal ulcerative colitis. A comparative trial vs Salofalk enema. The SAF-3 study group. Ardizzone S, Doldo P, Ranzi T, Sturniolo GC, Giglio LA, Annese V, D'Arienzo A, Gaia E, Gullini S, Riegler G, Valentini M, Massa P, Del Piano M, Rossini F, Guidetti CS, Pera A, Greinwald R, Porro GB

Gut 2000 Apr;46(4):487-92 Measurement of in vivo rectal mucosal cytokine and eicosanoid production in ulcerative colitis using filter paper. Carty E, De Brabander M, Feakins RM, Rampton DS

Inflamm Bowel Dis 2000 Feb;6(1):48-57; discussion 58 How to do without steroids in inflammatory bowel disease. Present DH

Nutrition 2000 Feb;16(2):87-90 Comparison of omega-3 fatty acids and sulfasalazine in ulcerative colitis. Dichi I, Frenhane P, Dichi JB, Correa CR, Angeleli AY, Bicudo MH, Rodrigues MA, Victoria CR, Burini RC

. Am J Gastroenterol 2000 Feb;95(2):469-73 The natural history of ulcerative proctitis: a multicenter, retrospective study. Gruppo di Studio per le Malattie Infiammatorie Intestinali (GSMII). Meucci G, Vecchi M, Astegiano M, Beretta L, Cesari P, Dizioli P, Ferraris L, Panelli MR, Prada A, Sostegni R, de Franchis R

J Gastrointest Surg 2000 Mar-Apr;4(2):201-6 Predicting the need for colectomy in pediatric patients with ulcerative colitis. Falcone RA Jr, Lewis LG, Warner BW

Eur J Gastroenterol Hepatol 2000 Jan;12(1):13-8 IOIBD questionnaire on the clinical use of azathioprine, 6-mercaptopurine,cyclosporin A and methotrexate in the treatment of inflammatory bowel diseases. Meuwissen SG, Ewe K, Gassull MA, Geboes K, Jewell D, Pallone F, Rachmilewitz D, Rask-Madsen J, Riddell BH, Sandborn BJ, Schmuck ML

Int J Colorectal Dis 1999 Nov;14(4-5):261-2 Long-term effects of a single course of nicotine treatment in acute ulcerative colitis: remission maintenance in a 12-month follow-up study. Guslandi M

Am J Gastroenterol 2000 Jan;95(1):171-6 Appendectomy and the development of ulcerative colitis: results of ametaanalysis of published case-control studies. Koutroubakis IE, Vlachonikolis IG

Jpn J Cancer Res 1999 Oct;90(10):1081-7 Genetic alterations in ulcerative colitis-associated neoplasia focusing on APC, K-ras gene and microsatellite instability. Umetani N, Sasaki S, Watanabe T, Shinozaki M, Matsuda K, Ishigami H, Ueda E, Muto T

World J Surg 2000 Jan;24(1):119-24 Changes in intestinal transit time after proctocolectomy assessed by thelactulose breath test. Bruewer M, Stern J, Herrmann S, Senninger N, Herfarth C

Br J Clin Pharmacol 1999 Oct;48(4):485-93 An oral formulation of nicotine for release and absorption in the colon: itsdevelopment and pharmacokinetics. Green JT, Evans BK, Rhodes J, Thomas GA, Ranshaw C, Feyerabend C, Russell MA

Scand J Gastroenterol 1999 Nov;34(11):1103-7 Ultrasonography in the evaluation of extension, activity, and follow-up ofulcerative colitis. Maconi G, Ardizzone S, Parente F, Bianchi Porro G

Pathol Int 1999 Oct;49(10):858-68 p53 immunohistochemistry of ulcerative colitis-associated with dysplasia and carcinoma. Sato A, MacHinami R

Aliment Pharmacol Ther 1999 Nov;13(11):1413-7 Rectal and colonic mesalazine concentration in ulcerative colitis: oral vs. oral plus topical treatment. Frieri G, Pimpo MT, Palumbo GC, Onori L, Viscido A, Latella G, Galletti B, Pantaleoni GC, Caprilli R

Jpn J Clin Oncol 1999 Sep;29(9):448-51 Ulcerative colitis patients with a family history of colorectal cancer should be subjected to close and careful surveillance. Matsuda K, Watanabe T, Shinozaki M, Yokoyama T, Sasaki S, Furukawa Y, Kanazawa T, Masaki T, Muto T

Aliment Pharmacol Ther 1999 Oct;13(10):1323-8 Low molecular weight heparin as adjuvant therapy in active ulcerative colitis.Torkvist L, Thorlacius H, Sjoqvist U, Bohman L, Lapidus A, Flood L, Agren B, Raud J, Lofberg R

Dis Colon Rectum 1999 Oct;42(10):1318-24 Effects of restorative proctocolectomy on renal and adrenal function. Huber FX, Stern J, Hinz U, Werle E, Haack D, Kienle P, Heuschen U, Aulmann M, Decker-Baumann C, Herfarth C

Dis Colon Rectum 1999 Oct;42(10):1311-7 Pattern of mucosal adaptation in acute and chronic pouchitis. Stallmach A, Moser C, Hero-Gross R, Muller-Molaian I, Ecker KW, Feifel G, ZeitzM

Int J Pharm 1999 Nov 10;190(1):21-34 Development of a rectal nicotine delivery system for the treatment of ulcerativecolitis. Dash AK, Gong Z, Miller DW, Huai-Yan H, Laforet J

Hepatogastroenterology 1999 Jul-Aug;46(28):2343-6 Practicality of 5-aminosalicylic suppositories for long-term treatment ofinactive distal ulcerative colitis. Casellas F, Vaquero E, Armengol JR, Malagelada JR

Am J Gastroenterol 1999 Oct;94(10):2918-22 The effects of migration on ulcerative colitis: a three-year prospective studyamong Europeans and first- and second- generation South Asians in Leicester(1991-1994). Carr I, Mayberry JF

J Nucl Med 1999 Oct;40(10):1630-6 Scintigraphic imaging and absorption of a 5-aminosalicylic acid enema in patients with ileorectal anastomosis. Lisciandrano D, Benti R, Ranzi T, Baldassarri AR, Bruno A, Bianchi PA, Gerundini P

Gut 1999 Nov;45(5):686-92 Villous, hypermucinous mucosa in long standing ulcerative colitis shows highfrequency of K-ras mutations. Andersen SN, Lovig T, Clausen OP, Bakka A, Fausa O, Rognum TO

Eur J Gastroenterol Hepatol 1999 Aug;11(8):905-8 Oral microemulsion cyclosporin to reduce steroids rapidly in chronic active ulcerative colitis. Actis GC, Volpes R, Rizzetto M

Dig Dis Sci 1999 Sep;44(9):1899-901 Sucralfate and methylprednisolone enemas in active ulcerative colitis: a prospective, single-blind study. Wright JP, Winter TA, Candy S, Marks IS

Eur J Gastroenterol Hepatol 1999 Sep;11(9):1001-5 Extraintestinal manifestations of ulcerative colitis following restorative proctocolectomy. Thomas PD, Keat AC, Forbes A, Ciclitira PJ, Nicholls RJ

Gut 1999 Oct;45(4):546-52 Mesenteric blood flow is related to disease activity and risk of relapse inulcerative colitis: a prospective follow up study. Ludwig D, Wiener S, Bruning A, Schwarting K, Jantschek G, Fellermann K, Stahl M, Stange EF

Abdom Imaging 1999 Sep-Oct;24(5):497-505 Hydrocolonic sonography in the evaluation of colonic lesions. Dixit R, Chowdhury V, Kumar N

Lancet 1999 Aug 21;354(9179):635-9 Non-pathogenic Escherichia coli versus mesalazine for the treatment ofulcerative colitis: a randomised trial. Rembacken BJ, Snelling AM, Hawkey PM, Chalmers DM, Axon AT

Braz J Med Biol Res. 1999 Sep;32(9):1083-8. Infrequent p53 gene alterations in ulcerative colitis. Mattar R, Alexandrino AM, Laudanna AA

Am J Surg Pathol 1999 Aug;23(8):963-9 P53 and beta catenin expression in chronic ulcerative colitis--associated polypoid dysplasia and sporadic adenomas: an immunohistochemical study. Walsh SV, Loda M, Torres CM, Antonioli D, Odze RD

Am J Ther 1997 Apr;4(4):141-8 Nicotine: does it have a role in the treatment of ulcerative colitis? Slyk MP, Frazee LA

Aliment Pharmacol Ther 1999 Jun;13(6):713-8 Antibiotic combination therapy in patients with chronic, treatment-resistantpouchitis. Gionchetti P, Rizzello F, Venturi A, Ugolini F, Rossi M, Brigidi P, Johansson R,Ferrieri A, Poggioli G, Campieri M

Eur Radiol 1999;9(5):875-9 Double-contrast magnetic resonance examination of ulcerative colitis. Sardanelli F, de Cicco E, Renzetti P, Parodi RC, Calabrese M

Am J Gastroenterol 1999 Jun;94(6):1587-92 Intravenous cyclosporin in ulcerative colitis: a five-year experience. Cohen RD, Stein R, Hanauer SB

Am J Gastroenterol 1999 Jun;94(6):1551-5 Unfractioned heparin in the therapy of patients with highly active inflammatory bowel disease. Folwaczny C, Wiebecke B, Loeschke K

Am J Pathol 1999 Jun;154(6):1825-30 Genomic instability is an early event during the progression pathway of ulcerative-colitis-related neoplasia. Willenbucher RF, Aust DE, Chang CG, Zelman SJ, Ferrell LD, Moore DH 2nd, Waldman FM

J Pediatr Surg 1999 May;34(5):837-9; discussion 839-40 Restorative proctocolectomy in children with ulcerative colitis utilizing rectal mucosectomy with or without diverting ileostomy. Dolgin SE, Shlasko E, Gorfine S, Benkov K, Leleiko N

Aliment Pharmacol Ther 1999 May;13(5):569-75 Immunosuppressive therapy for ulcerative colitis: results of a nation-wide survey among consultant physician members of the British Society of Gastroenterology. Stack WA, Williams D, Stevenson M, Logan RF

Dis Colon Rectum 1999 Mar;42(3):398-402 Effect of restorative proctocolectomy on gastric acid secretion and serum gastrin levels: a prospective study. M'Koma AE, Lindquist K, Liljeqvist L

Dis Colon Rectum 1999 Mar;42(3):334-6 Protective effect of appendectomy on the development of ulcerative colitis: matched, case-control study. Dijkstra B, Bagshaw PF, Frizelle FA

Dis Colon Rectum 1999 Feb;42(2):225-30 Appendectomy, tonsillectomy, and risk of inflammatory bowel disease: case-controlled study in Crete. Koutroubakis IE, Vlachonikolis IG, Kapsoritakis A, Spanoudakis S, Roussomoustakaki M, Mouzas IA, Kouroumalis EA, Manousos ON

Am J Surg Pathol 1999 Apr;23(4):423-30 Biopsy diagnosis of colitis: possibilities and pitfalls. Tsang P, Rotterdam H

Drugs 1999 Mar;57(3):383-408 Oral delayed-release mesalazine: a review of its use in ulcerative colitis and Crohn's disease. Prakash A, Markham A

Mol Pathol 1998 Dec;51(6):327-32 Ki-67: a useful marker for the evaluation of dysplasia in ulcerative colitis. Andersen SN, Rognum TO, Bakka A, Clausen OP

Aliment Pharmacol Ther 1999 Mar;13(3):381-8 A new mesalazine gel enema in the treatment of left-sided ulcerative colitis: a randomized controlled multicentre trial. Gionchetti P, Ardizzone S, Benvenuti ME, Bianchi Porro G, Biasco G, Cesari P, D'albasio G, De Franchis R, Monteleone G, Pallone F, Ranzi T, Trallori G, Valpiani D, Vecchi M, Campieri M

Aliment Pharmacol Ther 1999 Mar;13(3):373-9 Is maintenance therapy always necessary for patients with ulcerative colitis in remission? Ardizzone S, Petrillo M, Imbesi V, Cerutti R, Bollani S, Bianchi Porro G